

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number  
**WO 01/58483 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 16/18**,  
16/12, A61K 39/395, 38/17, 31/7088, 39/42, 39/40, 35/16,  
47/48, 31/00 // (A61K 39/42, 39:395) (A61K 39/40,  
39:395) (A61K 39/395, 38:17) (A61K 39/395, 35:16)

Lane, Charlottesville, VA 22901 (US). **SUTHERLAND, William, M.** [US/US]; 4275 Viewmont Road, Earlysville, VA 22936 (US). **GOLDBERG, Joanna, B.** [US/US]; 295 Ipswich Place, Charlottesville, VA 22901 (US).

(21) International Application Number: PCT/US01/04020

(74) Agents: **BALDWIN, Geraldine, F.** et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(22) International Filing Date: 8 February 2001 (08.02.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:  
60/181,143 8 February 2000 (08.02.2000) US  
09/724,621 28 November 2000 (28.11.2000) US

(71) Applicant (*for all designated States except US*): **THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION** [US/US]; Suite 1-110, 1224 West Main Street, Charlottesville, VA 22903 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and





(75) Inventors/Applicants (*for US only*): **TAYLOR, Ronald, P.** [US/US]; 108 Kerry Lane, Charlottesville, VA 22901 (US). **LINDORFER, Margaret, A.** [US/US]; 108 Kerry

Published:

— with international search report

[Continued on next page]

(54) Title: METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES



(57) Abstract: The present invention relates to the treatment and prevention of viral infections, microbial infections, and septic shock by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing viral infection, microbial infection, or septic shock in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement components in combination with antibodies immunospecific for C3b(i). The present invention also relates to methods of treating and preventing viral infection or microbial infection in an animal comprising administering said animal antibodies that immunospecifically bind to one or more viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present invention further relates to methods of treating and preventing septic shock in an animal comprising administering said animal antibodies that immunospecifically bind to lipopolysaccharide, an endotoxin or a constituent of the outer wall of a gram negative bacteria in combination with antibodies immunospecific for C3b(i).

BEST AVAILABLE COPY

WO 01/58483 A3



**(88) Date of publication of the international search report:**  
18 April 2002

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04020

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/18 C07K16/12 A61K39/395 A61K38/17 A61K31/7088  
A61K39/42 A61K39/40 A61K35/16 A61K47/48 A61P31/00  
/(A61K39/42, 39:395), (A61K39/40, 39:395), (A61K39/395, 38:17),

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 87 06344 A (NILSSON ULF R; NILSSON S I  BO; SVENSSON KARL ERIK)  22 October 1987 (1987-10-22)  abstract  page 1, paragraphs 3,4  page 2, paragraph 4  page 4, paragraph 3 -page 5, paragraph 3  page 8, paragraph 2  page 23; table 3</p> <p style="text-align: center;">--- -/--</p>	1, 10, 38

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

31 August 2001

Date of mailing of the international search report

1 0. 09. 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Montrone, M

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04020

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 (A61K39/395,35:16)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H HUEMER ET AL: "Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein" IMMUNOLOGY, GB, OXFORD, vol. 79, no. 4, 1 August 1993 (1993-08-01), pages 639-647, XP002091631 ISSN: 0019-2805 abstract page 639, column 2, paragraph 2 -page 640, column 1, paragraph 1 page 640, column 1, paragraph 4 page 641; table 1 page 642, column 1, paragraph 2; figure 2 page 643, column 1, paragraph 1 -column 2, paragraph 5 page 645, column 1, paragraph 3 -column 2, paragraph 2 -/-	1,4,10, 37

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

31 August 2001

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montrone, M

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04020

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>-----</p> <p>MCCORMICK L.L. ET AL.: "Bispecific Antibodies Overcome the Opsonin-Receptor Mismatch of Cystic Fibrosis In Vitro" J. IMMUNOLOGY, vol. 158, 1997, pages 3474-3482, XP000999281 abstract page 3474, column 2, paragraphs 2,3 page 3475, column 1, paragraphs 1-3 page 3478, column 2, paragraph 2 -page 3481, column 2, paragraph 1</p>	1,10,17, 25-27, 29,30, 32-34, 38,39
X	<p>-----</p> <p>TAMERIUS J D ET AL: "DETECTION OF A NEOANTIGEN ON HUMAN COMPLEMENT C-3BI AND C-3D BY MONOCLONAL ANTIBODY" JOURNAL OF IMMUNOLOGY, vol. 135, no. 3, 1985, pages 2015-2019, XP001000801 ISSN: 0022-1767 abstract page 2015, column 2, paragraph 1 page 2017, column 2, paragraph 2 -page 2018, column 2, paragraph 3</p>	1,10
X	<p>-----</p> <p>VAPORCIYAN ARA A ET AL: "Enhanced generation of O-2- by human neutrophils via a complement iC3b/Mac-1 interaction." BIOLOGICAL SIGNALS, vol. 2, no. 3, 1993, pages 126-135, XP001000394 ISSN: 1016-0922 abstract page 127, column 2, paragraph 1 page 131, column 1, paragraph 2 -column 2, paragraph 1</p>	1,10
A	<p>-----</p> <p>DEMPSEY PW ET AL: "C3d OF COMPLEMENT AS A MOLECULAR ADJUVANT: BRIDGING INATE AND ACQUIRED IMMUNITY" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 271, 19 January 1996 (1996-01-19), pages 348-350, XP002095252 ISSN: 0036-8075 abstract</p>	1-9
P,X	<p>-----</p> <p>WO 00 15259 A (NARDIN ALESSANDRE ;SOKOLOFF MITCHELL M D (US); TAYLOR RONALD (US);) 23 March 2000 (2000-03-23) abstract page 1, column 11-18</p> <p>-----</p> <p>---/---</p>	1,10

## INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/US 01/04020

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CAMPBELL G A ET AL: "Mechanisms of binding of Brucella abortus to mononuclear phagocytes from cows naturally resistant or susceptible to brucellosis."  VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 41, no. 3-4, 1994, pages 295-306, XP001005480  ISSN: 0165-2427  abstract  page 296, paragraph 2  page 298, paragraph 2  page 300; table 1  page 301, paragraph 1 -page 302, paragraph 1</p>	1, 10, 38, 39
X	<p>NEWMAN S L ET AL: "DEPOSITION OF COMPLEMENT C-3B AND COMPLEMENT I-C-3B ONTO PARTICULATE ACTIVATORS OF THE HUMAN COMPLEMENT SYSTEM QUANTITATION WITH MONOCLONAL ANTIBODIES TO HUMAN COMPLEMENT C-3"  JOURNAL OF EXPERIMENTAL MEDICINE, vol. 161, no. 6, 1985, pages 1414-1431, XP001000368  ISSN: 0022-1007  page 1414, paragraph 1 -page 1415, paragraph 2  page 1417, paragraph 4; figure 1  page 1418, paragraph 2  page 1425, paragraphs 2,3  page 1426, paragraph 2  page 1427, paragraph 3</p>	1-4, 10-13, 32, 34, 38, 39
X	<p>KRETTLI A U ET AL: "BINDING OF COMPLEMENT C-3 FRAGMENTS TO THE TRYPANOSOMA-CRUZI SURFACE IN THE ABSENCE OF SPECIFIC ANTIBODIES AND WITHOUT ACTIVATION OF THE COMPLEMENT CASCADE"  CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 62, no. 2, 1985, pages 270-277, XP001000367  ISSN: 0009-9104  abstract  page 271, paragraph 5  page 274, paragraph 2 -page 276, paragraph 2; tables 3,4</p>	1, 2, 4, 10, 11, 13, 38

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/04020

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
1-18 (completely), 25-34 (partially), 35-39 (completely)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-9 (all completely), 25-34 (all partially), 35, 37

A composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies for use in reducing viral titer or ameliorating one or more symptoms associated with a viral infection. And bispecific antibodies thereof.

2. Claims: 10-18 (all completely), 25-34 (all partially), 36, 38, 39

A composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies for use in reducing microbial numbers or ameliorating one or more symptoms associated with a microbial infection. And bispecific antibodies thereof.

3. Claims: 19-24 (all completely), 25-34 (all partially)

A composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies for use in ameliorating one or more symptoms associated with a septic shock. And bispecific antibodies thereof.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/04020

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8706344 A	22-10-1987	SE 452065 B AU 7286887 A EP 0263161 A JP 63503089 T SE 8601644 A	09-11-1987 09-11-1987 13-04-1988 10-11-1988 12-10-1987
WO 0015259 A	23-03-2000	AU 5917299 A EP 1112086 A	03-04-2000 04-07-2001

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number  
**WO 01/58483 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 39/395**

(21) International Application Number: **PCT/US01/04020**

(22) International Filing Date: **8 February 2001 (08.02.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
60/181,143 8 February 2000 (08.02.2000) US  
09/724,621 28 November 2000 (28.11.2000) US

(71) Applicant (for all designated States except US): **THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION** [US/US]; Suite 1-110, 1224 West Main Street, Charlottesville, VA 22903 (US).

(74) Agents: **BALDWIN, Geraldine, F. et al.**; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **TAYLOR, Ronald, P.** [US/US]; 108 Kerry Lane, Charlottesville, VA 22901 (US). **LINDORFER, Margaret, A.** [US/US]; 108 Kerry Lane, Charlottesville, VA 22901 (US). **SUTHERLAND, William, M.** [US/US]; 4275 Viewmont Road, Earlysville, VA 22936 (US). **GOLDBERG, Joanna, B.** [US/US]; 295 Ipswich Place, Charlottesville, VA 22901 (US).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES**



(57) Abstract: The present invention relates to the treatment and prevention of viral infections, microbial infections, and septic shock by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing viral infection, microbial infection, or septic shock in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement components in combination with antibodies immunospecific for C3b(i). The present invention also relates methods of treating and preventing viral infection or microbial infection in an animal comprising administering said animal antibodies that immunospecifically bind to one or more viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present

invention further relates methods of treating and preventing septic shock in an animal comprising administering said animal antibodies that immunospecifically bind to lipopolysaccharide, an endotoxin or a constituent of the outer wall of a gram negative bacteria in combination with antibodies immunospecific for C3b(i).

WO 01/58483 A2

## METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES

---

### 1. INTRODUCTION

5       The present invention relates to methods of treating and preventing viral infection, microbial infection, or septic shock in an animal comprising administering to said animal antibodies specific for C3b(i). The present invention also relates to methods of treating and preventing viral infection, microbial infection, or septic shock in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement  
10 components in combination with antibodies immunospecific for C3b(i). The present invention also relates methods of treating and preventing viral infection or microbial infection in an animal comprising administering to said animal antibodies that immunospecifically bind to one or more viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present invention also  
15 relates methods of treating and preventing septic shock in an animal comprising administering said animal antibodies that immunospecifically bind to lipopolysaccharide, an endotoxin or a constituent of the outer wall of a gram negative bacteria in combination with antibodies immunospecific for C3b(i). The present invention further relates to pharmaceutical compositions for the treatment and prevention of viral infection, microbial  
20 infection, and septic shock comprising antibodies immunospecific for C3b(i).

### 2. BACKGROUND OF THE INVENTION

The complement system which is composed of some 21 plasma proteins plays an important role in the human immune system, both in the resistance to infections and in the  
25 pathogenesis of tissue injury. The activated products of the complement system attract phagocytic cells and greatly facilitate the uptake and destruction of foreign particles by opsonization. There are two distinct pathways for activating complement, the classical pathway and the alternate pathway, that result in conversion of C3 to C3b and subsequent responses (e.g., the formation of the membrane attack complex ("MAC")). Activation of  
30 the classical pathway is initiated by antigen-antibody complexes or by antibody bound to cellular or particulate antigens. The alternate pathway is activated independent of antibody by complex polysaccharides in pathogens such as bacterial wall constituents, bacterial lipopolysaccharides (LPS), and cell wall constituents of yeast (zymosan).

The classic complement pathway is initiated by the binding of C1 to immune  
35 complexes containing IgG or IgM antibodies. Activated C1 cleaves C2 and C4 into active components, C2a and C4b. The C4b2a complex is an active protease called C3 convertase,

and acts to cleave C3 into C3a and C3b. C3b forms a complex with C4b2a to produce C4b2a3b, which cleaves C5 into C5a and C5b. C5b combines with C6, and the C5b6 complex combines with C7 to form the ternary complex C5b67. The C5b67 complex binds C8 to form the C5b678 complex which in turn binds C9 and results in the generation of the  
5 C5-C9 MAC. The insertion of the MAC into the cell membrane results the formation of a transmembrane channel that causes cell lysis.

In the alternative pathway, conversion of C3 to C3b (or C3i) produces a product that can combine with factor B, giving C3bB (or C3iB). These complexes are acted upon by factor D to generate C3bBb, which is a C3 convertase capable of cleaving more C3 to C3b,  
10 leading to more C3bBb and even more C3 conversion. Under certain circumstances the C3bBb complex is stabilized by association with the positive regulator properdin (P) by association of C3b and Bb. The C3 convertases can associate with an additional C3b subunit to form the C5 convertase, C3bBbC3b, which is active in the production of the C5-C9 MAC.

15 In both the classical and alternative pathways, the critical step in the activation of complement is the proteolytic conversion of C3 to the fragments C3b and C3a. C3a is an anaphylatoxin that attracts mast cells to the site of challenge, resulting in local release of histamine, vasodilation and other inflammatory effects. The nascent C3b has an ability to bind to surfaces around its site of generation and functions as a ligand for C3 receptors  
20 mediating, for example, phagocytosis.

Endogenous cell surfaces normally exposed to complement are protected by membrane-bound regulators such as decay accelerating factor ("DAF"), C59 ("protectin"), MCP, and the soluble C1 inhibitor or C1NH. DAF and MCP are responsible for limiting production of C3b and insure the generation of inactive forms of C3b, C3bi and C3dg from  
25 C3b. CD59 prevents attack of the MAC, which would otherwise destroy the cancer cell. C1 inhibitor binds to the active subcomponents of C1, C1r and C1s, and inhibits their activity.

## 2.1. CANCER TREATMENT

Despite advances in prevention and early detection, refinements in surgical  
30 technique, and improvements in adjuvant radiotherapy and chemotherapy, the ability to cure many patients of cancer remains elusive. This is especially pertinent to prostate cancer, which remains the most prevalent visceral tumor in American men, with approximately 180,000 new cases and nearly 40,000 deaths expected in 1999 (Landis et al., 1999, Cancer J Clin 49: 8-31). The continuing challenge of prostate cancer treatment is the successful  
35 management and eradication of recurrent, metastatic, and hormone-refractory disease,

which accounts for the vast majority of prostate cancer-specific morbidity and mortality (Small, 1998, *Drugs and Aging* 13:71-81).

Many treatment modalities currently under investigation for prostate and other cancers depend upon tissue-specific delivery of anti-neoplastic agents. One  
5 immunotherapeutic approach involves conjugating cytotoxic agents to monoclonal antibodies (mAbs) specific for a particular cancer cell epitope. In this manner, the therapeutic agents can be delivered at a high therapeutic dose directly, and selectively, to the tumor site, thereby minimizing injury to healthy tissue (Bach et al., 1993, *Immunol Today* 14:421-5; Reithmuller et al., 1993, *Cur. Op. Immunol* 5:732-9; and Gruber et  
10 al., 1996, *Spring Sem Immunopath* 18:243-51). This method first requires the identification of specific epitopes for each cancer type. Such candidate epitopes must be expressed at high levels on the cancer cells compared to normal tissue. Second, this method requires the development of high affinity mAbs specific for these epitopes and these mAbs must show minimal cross-reactivity with self tissue. The biological mechanism of killing with mAbs  
15 will be variable, depending upon the epitopes identified on the cancer cells, and the effector functions of the specific mAb isotype. However, due to antigenic modulation and/or mutation, the cancer cells may reduce the available levels of the target epitope per cell, or eliminate it from their surface altogether. Thus, the use of mAbs in cancer diagnosis and treatment remains problematic.

20 A more widely applicable approach to treatment of cancer with mAbs would be to identify a ubiquitous antigenic site, present on virtually all cancer cells, and then to develop a panel of mAbs specific for this antigen. A voluminous literature reveals that cancer cells share certain common characteristics. Many types of human cancer cells are characterized by substantial abnormalities in the glycosylation patterns of their cell-surface proteins and  
25 lipids (Hakomori et. al., 1996, *Canc Res.* 56:5309-18; Castronovo et al., 1989, *J Nat Canc Inst* 81:212-6; Springer et al., 1984, *Science* 224:1198-206; and Springer et al., 1997, *J Mol Med* 75:594-602). These differences have led to the identification of antigenic determinants on cancer cells which are expressed at far lower levels on normal cells. Natural IgM antibodies to these epitopes are present in the circulation, and the interaction of such IgM  
30 antibodies with these cancer cell surface antigens leads to activation of complement and covalent coupling of complement activation products (C3b and its fragments, collectively referred to as C3b(i)) to the tumor cells (Okada et al., 1974, *Nature* 248:521-25; Irie et. al., 1974, *Science* 186:454-456; Desai et al., 1995, *J Immunol Methods* 188:175-85; Vetvicka et al., 1996, *J Clin Invest* 98:50-61; Vetvicka et al., 1997, *J Immunol* 159:599-605; and  
35 Vetvicka et al., 1999, *Clin Exp Immunol* 115:229-35). Although relatively large amounts of C3b(i) can be deposited on cancer cells, the concomitant expression of high levels of

membrane-associated complement control proteins (*e.g.*, decay accelerating factor ("DAF"), membrane cofactor protein ("MCP"), and, in particular, "protectin" *i.e.*, CD59) usually prevents complement-mediated lysis (Cheung et al., 1988, J Clin Invest 81:1122-8; Gorter et al., 1996, Lab Invest 74:1039-49; Maenpaa et al., 1996, Am J Path 148:1139-52; and Li et al., 1997, Int J Canc 71:1049-55). Further, several investigators have established that in most cases, cancer patients have substantially *lowered* levels of the potentially protective IgM antibodies. Thus, in many cases the cancer cells cannot easily be killed by complement activation because of the reduced levels of protective IgM antibody and the increased expression of human complement control proteins on their surface.

10

## 2.2. ROLE OF COMPLEMENT IN INFECTIONS

Innate immunity allows humans and most animals to respond to foreign organisms even before the initiation of the immune response. One of the most important aspects of innate immunity involves the complement system (Cooper, N. R. Complement and viruses. Volanakis, J. B. and Frank, M. M. The Human Complement System in Health and Disease. 18, 393-408. (1998) New York, Marcel Dekker, Inc.; and Petry, F. and Loos, M. Bacteria and complement. Volanakis, I. E. and Frank, M. M. The Human Complement System in Health and Disease. 171, 375-392. (1998) New York, Marcel Dekker, Inc.). It is now well-documented that a wide variety of bacteria, viruses and other microorganisms activate complement in the immunologically naive individual (Peterson et al., 1978, Infect. Immun. 19:943; Verbrugh et al., 1982, J. Immunol. 129:1681; Newman et al., 1985, J. Exp. Med. 161:1414; Seelen et al., 1995, Immunol. 84:653; Wagner et al., 1998, J. Immunol. 160:1936; Bakker et al., 1992, AIDS 6:35; Hiavacek et al., 1999, Proc. Natl. Acad. Sci. 96:14681; Schmitz et al., 1994, J. Immunol. 153:1352; Tacnet-Delorme et al., 1999, J. Immunol. 162:4088; Joling et al., 1993, J. Immunol. 150:1065; Dominguez et al., 1999, J. Exp. Med. 189:25; and Washburn et al., 1991, Molec. Immunol. 28:465). These include, but are not limited to, both gram positive and gram negative bacteria, and the virus which causes AIDS, HIV. As a consequence of complement activation, these organisms are covalently labeled with complement activation fragments, and in particular with C3b(i). Moreover, in individuals with previous exposure to these pathogens (either through immunization or previous infection), specific antibodies will bind to the pathogens and also activate complement and promote C3b(i) deposition. Although in many instances this complement activation ultimately leads to the clearance and destruction of the microorganism, in some cases the C3b(i)-labeled invader remains in the circulation and can still infect susceptible tissues and organs. In fact, there are many examples of microorganisms which actually use these covalently attached C3b(i) molecules to gain entry

- into cells (which have receptors for C3bCi)) and establish productive infections (Bakker et al., 1992, AIDS 6:35; Tacnet-Delorme et al., 1999, J. Immunol. 162:4088; Cooper, N. R. Complement and viruses. Volanakis, J. B. and Frank, M. M. The Human Complement System in Health and Disease. 18, 393-408. 1998. New York, Marcel Dekker, Inc.; and
- 5 Petry, F. and Loos, M. Bacteria and complement. Volanakis, I. E. and Frank, M. M. The Human Complement System in Health and Disease. 171, 375-392. (1998) New York, Marcel Dekker, Inc.). Several lines of evidence indicate that C3b(i)-opsonized HIV can persist in the body bound to the surface of dendritic cells for very long periods of time, and this cell-bound HIV may represent one of the main obstacles to the permanent elimination
- 10 of HIV from the body (Hiavacek et al., 1999, Proc. Natl. Acad. Sci. 96:14681; and Schmitz, et al., 1994, J. Immunol. 153:1352).

Citation of a reference in this section or any section of this application shall not be construed as an admission that such reference is prior art to the present invention.

### 15 3. SUMMARY OF THE INVENTION

The present invention encompasses compositions comprising antibodies immunospecific for C3b(i) and methods for the treatment and prevention of viral infection, microbial infection and septic shock in an animal comprising administering such compositions to said animal. In particular, the present invention provides methods for

20 treating or preventing viral infection, microbial infection, and septic shock in animal comprising administering to said animal a therapeutically or prophylactically effective amount of an antibody immunospecific for C3b(i), an antibody immunospecific for C3b(i) linked (*e.g.*, covalently linked) to a second molecule (*e.g.*, an IgM antibody, an IgG antibody, a glycoprotein or a glycolipid), a nucleic acid sequence encoding an antibody

25 immunospecific for C3b(i), or a nucleic acid sequence encoding an antibody immunospecific for C3b(i) linked (*e.g.*, covalently linked) to a second molecule. The present invention also provides methods for the treatment or prevention of viral infection, microbial infection or septic shock in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement components in combination with

30 anti-C3b(i) antibodies. The present invention also provides methods for the treatment or prevention of viral infection or microbial infection in an animal comprising administering to said animal antibodies immunospecific for one or more viral antigens or microbial antigens, respectively, in combination with anti-C3b(i) antibodies. The present invention also provides methods for the treatment or prevention of septic shock in an animal comprising

35 administering to said animal antibodies immunospecific for lipopolysaccharide, an

endotoxin, or a constituent of the outer wall of a gram negative bacteria (*e.g.*, a constituent of the outer wall of *Shigella* or *E. coli*) in combination with anti-C3b(i) antibodies.

The present invention also provides compositions comprising one or more antibodies immunospecific for C3b(i) or C3b(i) linked to a second molecule, in an amount effective for the treatment or prevention of a viral infection, a microbial infection, or septic shock in an animal. The present invention also provides compositions comprising one or more nucleic acid molecules encoding one or more antibodies immunospecific for C3b(i) or C3b(i) linked to a second molecule, in an amount effective for the treatment or prevention of a viral infection, a microbial infection, or septic shock in an animal. The present invention further provides a composition comprising one or more bispecific antibodies which are immunospecific for C3b(i) or C3b(i) linked to a second molecule and an effector cell receptor or antigen, in an amount effective for the treatment or prevention of a viral infection, a microbial infection or septic shock in an animal.

### 3.1. DEFINITIONS

The term "C3b(i)" as used herein refers to C3b and its fragments, including, but not limited to, C3b(i), C3b, and C3d.

As used herein, the terms "antibody immunospecific for C3b(i)", "antibodies immunospecific for C3b(i)", "C3b(i) specific antibodies", "anti-C3b(i) antibodies" and the like refer one or more antibodies that specifically bind to C3b(i), a fragment of C3b(i), C3b(i) linked (*e.g.*, covalently linked) to a second molecule, or a fragment of C3b(i) linked (*e.g.*, covalently linked) to a second molecule and do not non-specifically bind to polypeptides unrelated to C3b(i). Anti-C3b(i) antibodies may cross-react with other, non-C3b(i) antigens. Preferably, anti-C3b(i) antibodies do not cross-react with other antigens. Anti-C3b(i) antibodies can be identified, for example, by immunoassays or other techniques known to those of skill in the art. In a preferred embodiment, anti-C3b(i) antibodies immunospecifically bind to C3b(i) covalently linked to a second molecule. In another preferred embodiment, anti-C3b(i) antibodies preferentially bind to C3b(i)-opsonized cancer cells, and not to C3b(i) in the milieu. In another preferred embodiment, anti-C3b(i) antibodies preferentially bind to C3b(i) deposited on viruses or microbes, and not C3b(i) in the milieu.

In certain embodiments, the "second molecule" that C3b(i) is linked to is IgG or IgM. In certain other embodiments, the "second molecule" that C3b(i) is linked to is a cancer cell antigen such as, *e.g.*, a protein, glycoprotein, peptide, polypeptide, or glycolipid differentially or preferentially expressed by cancer cells. In certain other embodiments, the



"second molecule" that C3b(i) is linked to is a microbial or viral antigen. Preferably, C3b(i) is covalently linked to a second molecule.

The term "antibodies immunospecific for one or more cancer antigens, viral antigens, or microbial antigens" and the like as used herein refer to antibodies thereof that immunospecifically bind to cancer antigens, viral antigens, or microbial antigens and do not non-specifically bind to other polypeptides. Antibodies that immunospecifically bind to cancer antigens, viral antigens, or microbial antigens may have cross-reactivity with other antigens. Preferably, antibodies that immunospecifically bind to cancer antigens, viral antigens, or microbial antigens do not cross-react with other antigens. Antibodies that immunospecifically bind to cancer antigens, viral antigens, or microbial antigens can be identified, for example, by immunoassays or other techniques known to those of skill in the art.

The term "fragment" as used herein refers to a peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous amino acid residues, at least contiguous 80 amino acid residues, at least contiguous 90 amino acid residues, at least contiguous 100 amino acid residues, at least contiguous 125 amino acid residues, at least 150 contiguous amino acid residues, at least contiguous 175 amino acid residues, at least contiguous 200 amino acid residues, or at least contiguous 250 amino acid residues of the amino acid sequence of a cancer cell peptide or polypeptide (*e.g.*, a peptide or polypeptide preferentially or differentially expressed on a cancer cell), a viral peptide or polypeptide, a microbial peptide or polypeptide or an antibody that immunospecifically binds to C3b(i).

The term "fusion protein" as used herein refers to a polypeptide that comprises an amino acid sequence of an antibody or fragment thereof and an amino acid sequence of a heterologous polypeptide (*i.e.*, an unrelated polypeptide).

The term "host cell" as used herein refers to the particular subject cell transfected with a nucleic acid molecule and the progeny or potential progeny of such a cell. Progeny of such a cell may not be identical to the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur in succeeding generations or integration of the nucleic acid molecule into the host cell genome.

An "isolated" or "purified" antibody or polypeptide is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when

chemically synthesized. The language "substantially free of cellular material" includes preparations of an antibody or a polypeptide in which the antibody or polypeptide is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, an antibody or a polypeptide that is substantially free of cellular material includes preparations of antibody or polypeptide having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the antibody or polypeptide is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When the antibody or polypeptide is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, *i.e.*, it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the antibody or polypeptide have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the antibody or polypeptide fragment of interest. In a preferred embodiment, antibodies of the invention are isolated or purified.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a preferred embodiment, nucleic acid molecules encoding antibodies of the invention are isolated or purified.

In certain embodiments of the invention, a "prophylactically effective amount" is the amount of a composition of the invention that reduces the incidence of cancer, viral infection, microbial infection, or septic shock in an animal. Preferably, the incidence of cancer, viral infection, microbial infection or septic shock in an animal is reduced by at least 2.5 %, at least 5 %, at least 10 %, at least 15%, at least 25 %, at least 35 %, at least 45%, at least 50 %, at least 75%, at least 85 %, by at least 90 %, at least 95 %, or at least 99 % in an animal administered a composition of the invention relative to an animal or group of animals (*e.g.*, two, three, five, ten or more animals) not administered a composition of the invention.

In certain embodiments of the invention, a "therapeutically effective amount" is the amount of a composition of the invention that reduces the severity, the duration and/or the symptoms associated with cancer, viral infection, microbial infection, or septic shock in an animal. In certain other embodiments of the invention, a "therapeutically effective amount"

is the amount of a composition of the invention that results in a reduction in viral titer or microbial titer by at least 2.5 %, at least 5 %, at least 10 %, at least 15%, at least 25 %, at least 35 %, at least 45%, at least 50 %, at least 75%, at least 85 %, by at least 90 %, at least 95 %, or at least 99 % in an animal administered a composition of the invention relative to the viral titer or microbial titer in an animal or group of animals (*e.g.*, two, three, five, ten or more animals) not administered a composition of the invention. In certain other embodiments, a "therapeutically effective amount" is the amount of a composition of the invention that results in a reduction of the growth or spread of cancer by at least 2.5 %, at least 5 %, at least 10 %, at least 15%, at least 25 %, at least 35 %, at least 45%, at least 50 %, at least 75%, at least 85 %, by at least 90 %, at least 95 %, or at least 99 % in an animal administered a composition of the invention relative to the growth or spread of cancer in an animal or group of animals (*e.g.*, two, three, five, ten or more animals) not administered a composition of the invention.

#### 15           4.       BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 (A-D). Representative flow cytometry data from a study with serum from a normal donor (A, B) and a cancer patient (C, D). Measurement of C3b(i) (A, C) and IgM (B, D) deposition on C4-2 human prostate cancer cells is shown. Abundant C3b(i) is deposited on C4-2 cancer cells in response to the addition of normal human serum; this opsonization appears to be facilitated by both the classical and alternative complement pathways. After opsonization with serum from a prostate cancer patient, significantly less C3b(i) and IgM are deposited on the tumor cells (C, D). C3b(i) deposition via the alternative pathway (serum with Mg-EGTA), however, is comparable for both the normal and cancer patient serum, suggesting that the alternative pathway of the complement system remains intact in prostate cancer patient serum.

FIG. 2 (A-B). Flow cytometry (A) and radioimmunoassay (B) data demonstrating that removal of IgM from AB-positive serum results in a large reduction in the amount of C3b(i) that is deposited on LNCaP (A) or C4-2 (B) cells. C3b(i) deposition can be restored with either whole normal human plasma (A, B) (*e.g.*, plasma / IgM-depleted serum), which provides a source of human IgM, or with purified IgM/IgM-depleted serum (B).

FIG. 3 (A-B). Radioimmunoassay data demonstrating that complement activation generates between 50,000 and 500,000 C3b(i) epitopes/opsonized cancer cell (net binding, background subtracted), as defined by binding of both <sup>125</sup>I-labeled mAb 7C12 and 3E7. In panel A, an AB-positive serum was used for opsonization and, after three washes, cells were probed with differing amounts of the two mAb. Alternatively, mAb 3E7 was added to the cells just before the serum, and was present during opsonization. In panel B, AB-positive

serum was used in conjunction with the 1- $\mu$ g/ml and 10- $\mu$ g/ml probes, and an AB-positive citrated plasma (different donor from that in A) was used for the 3- $\mu$ g/ml probes

FIG. 4. Flow cytometry results from surveys of sera from normal donors and patients with prostate cancer. Binding of human immunoglobulin to LNCaP and C4-2 prostate cancer cells was measured. Significant differences were determined by t-tests.

FIG. 5 (A-B). Immunohistochemical staining of normal (A) and neoplastic (B) human prostate tissue after incubation with anti-C3b(i) mAb.

FIG. 6. Rosetting experiment using erythrocytes and opsonized LNCaP prostate cancer cells incubated in plasma in the presence of an anti-CR1 X anti-C3b(i) bispecific monoclonal antibody complex (7G9 X 3E7).

FIG. 7 (A-B). *In vitro* killing of LNCaP (A) and C4-2 (B) prostate cancer cells using  $^{131}$ I-labeled mAbs. Dashed line (---) delineates normal serum opsonized cells treated with  $^{131}$ I-labeled irrelevant mAbs; dotted line (....) delineates non-opsonized cells treated with  $^{131}$ I-anti-Cb3(i) mAbs; solid line (—) delineates normal serum opsonized cells treated with  $^{131}$ I-labeled anti-C3b(i) mAbs. Measured as cell proliferation relative to non-treated cells.

FIG. 8. The schematic illustrates the steps of the invention, all of which occur on the cell surface of tumor cells within the body of the cancer patient. In the first step, human IgM (either endogenous, or infused into the patient) binds to specific sites on the cancer cell. In the second step, complement (either endogenous, or infused into the patient as fresh plasma) is activated, and the resulting proteolytic fragment C3b(i) is deposited on the surface of the cancer cell. In the third step, a mAb specific for the C3b(i) epitope is administered. The mAb can be associated with a toxic, enzymatic, genetic, differentiating, and/or imaging agent (therefore it is an "effector mAb"), which results in the destruction or imaging of the cancer cell.

FIG. 9. Red cell binding experiment using erythrocytes and opsonized Rajii cells. Rajii cells treated with: serum alone; EDTA treated serum alone; serum and Rituximab; EDTA treated serum and Rituximab; serum and anti-C3b(i) X anti-CR1 bispecific monoclonal antibody complexes; EDTA treated serum and anti-C3b(i) X anti-CR1 bispecific monoclonal antibody complexes; serum, Rituximab, and anti-C3b(i) X anti-CR1 bispecific monoclonal antibody complexes; and EDTA treated serum Rituximab, and anti-C3b(i) X anti-CR1 bispecific monoclonal antibody complexes.

FIG. 10. Red cell binding experiment using erythrocytes and opsonized Rajii cells. Rajii cells treated with: washed whole blood reconstituted serum alone; washed whole blood reconstituted serum and Rituximab; washed whole blood reconstituted serum and anti-C3b(i) X anti-CR1 bispecific monoclonal antibody complexes; and washed whole

blood reconstituted serum, Rituximab, and anti-C3b(i) X anti-CR1 bispecific monoclonal antibody complexes; washed whole blood reconstituted serum, Rituximab (15'), and anti-C3b(i) X anti-CR1 bispecific monoclonal antibody complexes; and washed whole blood reconstituted serum, anti-C3b(i) X anti-CR1 bispecific monoclonal antibody (15'), and  
5 Rituximab.

## 5. DETAILED DESCRIPTION OF THE INVENTION

The present invention encompasses compositions comprising one or more antibodies immunospecific for C3b(i) and the use of such compositions in the treatment and prevention  
10 of cancer, viral infection, microbial infection, and septic shock. The present invention provides methods for treating or preventing cancer, viral infection, microbial infection, or septic shock in an animal, said methods comprising administering to said animal a therapeutically or prophylactically effective amount of one or more antibodies immunospecific for C3b(i) or C3b(i) linked to a second molecule. The present invention  
15 provides methods for treating or preventing cancer, viral infection, microbial infection, or septic shock in an animal, said methods comprising administering to said animal IgG antibodies, IgM antibodies, and/or one or more complement components in combination with a therapeutically or prophylactically effective amount of one or more antibodies immunospecific for C3b(i) or C3b(i) linked to a second molecule. The present invention  
20 also provides methods for treating or preventing cancer, viral infection, or microbial infection in an animal, said methods comprising administering to said animal one or more antibodies immunospecific for one or more cancer antigens, viral antigens, or microbial antigens, respectively, in combination with one or more antibodies immunospecific for C3b(i) or C3b(i) linked to a second molecule. The present invention further provides  
25 methods for treating or preventing septic shock in an animal, said methods comprising administering to said animal one or more antibodies immunospecific for lipopolysaccharide (LPS), an endotoxin, or a constituent of the outer wall of a gram negative bacteria (*e.g.*, the outer wall of *E. coli*) in combination with one or more antibodies immunospecific for C3b(i) or C3b(i) linked to a second molecule.

30 In accordance with the present invention, antibodies immunospecific for C3b(i) are administered to an animal, preferably a mammal and most preferably a human, to treat or prevent cancer, viral infection, microbial infection, or septic shock. The antibodies of the present invention comprise monoclonal antibodies, polyclonal antibodies, bispecific antibodies, humanized antibodies, human antibodies, chimeric antibodies, single chain  
35 antibodies, sFvs, idiotypic antibodies, Fab fragments, and F(ab') fragments, fragments produced by a Fab expression library, and epitope-binding fragments. In a specific embodiment, monoclonal antibodies immunospecific for C3b(i) are administered to an

- animal, preferably a mammal and most preferably a human, to treat or prevent cancer, viral infection, microbial infection, or septic shock. In a preferred embodiment, monoclonal antibodies immunospecific for C3b(i) covalently linked to a second molecule (*e.g.*, an IgM antibody, an IgG antibody, a glycoprotein or glycolipid) are administered to an animal,
- 5 preferably a mammal and most preferably a human, to treat or prevent cancer, viral infection, microbial infection, or septic shock. In another embodiment, monoclonal antibodies immunospecific for C3b(i) are conjugated to a therapeutic moiety such as an antibiotic, a chemotherapeutic cytotoxin, *e.g.*, a cytostatic or cytocidal agent (*e.g.*, paclitaxol, cytochalasin B or diphtheria toxin), a thrombotic or anti-angiogenic agent or a
- 10 radioactive label. In another embodiment, monoclonal antibodies immunospecific for C3b(i) are conjugated to a detectable substrate such as, *e.g.*, an enzyme, fluorescent marker, luminescent material, bioluminescent material, or radioactive material. In yet another embodiment, the valency of monoclonal antibodies immunospecific for C3b(i) are increased to that, for example, of a dimer or an IgM-like pentamer.
- 15 In a preferred embodiment, bispecific antibodies which are immunospecific for C3b(i) and an effector cell receptor or antigen are administered to an animal, preferably a mammal and most preferably a human, to treat, or prevent cancer, viral infection, microbial infection, or septic shock. The term "effector cell" as used herein refers to a cell which is involved in a cell-mediated immune response. Examples of effector cells include, but are
- 20 not limited to, monocytes, macrophages, dendritic cells, neutrophils, natural killer cells, lymphocytes and erythrocytes. In one embodiment, anti-C3b(i) heteropolymer constructs (bispecific monoclonal complexes) bound *ex vivo* to an effector cell via a cell surface receptor are administered to an animal, preferably a mammal and most preferably a human, to treat or prevent cancer, viral infection or microbial infection. Cell surface receptors
- 25 include, but are not limited to, CR1, CR2, CR3, CR4, human Fc $\gamma$  receptors CD16, CD32 and CD64, and the Fc receptor for IgA, CD89. In a preferred embodiment, anti-C3b(i) heteropolymer constructs bound *ex vivo* to erythrocytes via CR1 are administered to an animal, preferably a mammal and most preferably a human, to treat, inhibit or prevent cancer, viral infection, microbial infection, or septic shock.
- 30 In a preferred embodiment, bispecific diabodies which are antibody fragments immunospecific for C3b(i) and a complement component are administered to an animal, preferably a mammal and most preferably a human, to treat or prevent cancer, viral infection, microbial infection, or septic shock. In accordance with this embodiment, the diabodies are capable of recruiting complement components. In another embodiment,
- 35 bispecific diabodies which are immunospecific for C3b(i) and C1q are administered to an animal, preferably a mammal and most preferably a human, to treat or prevent cancer, viral

infection, microbial infection, or septic shock. Methods of preparing diabodies are taught in U.S. Patent No. 5,837,242, which is incorporated herein in its entirety.

The present invention encompasses the administration of IgG antibodies and/or IgM antibodies in combination with one or more anti-C3b(i) antibodies to animals to facilitate the opsonization of cancer cells, viruses, and microbes. In one embodiment, IgG antibodies and/or IgM antibodies are administered to an animal prior to, subsequent to, or concomitantly with the administration of one or more antibodies immunospecific for C3b(i) to treat or prevent cancer, viral infection, microbial infection, or septic shock. In a preferred embodiment, IgG antibodies and/or IgM antibodies are administered to an animal prior to the administration of one or more antibodies immunospecific for C3b(i) to treat or prevent cancer, viral infection, microbial infection or septic shock. In a specific embodiment, one or more antibodies immunospecific for one or more cancer cell antigens are administered to an animal prior to, subsequent to, or concomitantly with the administration of one or more antibodies immunospecific for C3b(i), in an amount effective for the treatment or prevention cancer. In a preferred embodiment, one or more antibodies immunospecific for one or more cancer cell antigens are administered to an animal prior to the administration of one or more antibodies immunospecific for C3b(i), in an amount effective for the treatment or prevention cancer. Examples of cancer cell antigens include, but are not limited to, improperly glycosylated cell-surface proteins and lipids.

In a specific embodiment, one or more antibodies used in cancer immunotherapy are administered to an animal prior to, subsequent to, or concomitantly with the administration of one or more anti-C3b(i) antibodies, in an amount effective for the treatment or prevention cancer. In a preferred embodiment, one or more antibodies used in cancer immunotherapy are administered to an animal prior to the administration of one or more anti-C3b(i) antibodies, in an amount effective for the treatment or prevention cancer. Examples of antibodies used in cancer immunotherapy include, but are not limited to: Herceptin® (Trastuzumab; Genetech, CA) which is a humanized anti-HER2 monoclonal antibody for the treatment of patients with metastatic breast cancer; Retuxan® (rituximab; Genentech) which is a chimeric anti-CD20 monoclonal antibody for the treatment of patients with non-Hodgkin's lymphoma; OvaRex (AltaRex Corporation, MA) which is a murine antibody for the treatment of ovarian cancer; Panorex (Glaxo Wellcome, NC) which is a murine IgG<sub>2a</sub> antibody for the treatment of colorectal cancer; BEC2 (ImClone Systems Inc., NY) which is murine IgG antibody for the treatment of lung cancer; IMC-C225 (Imclone Systems Inc., NY) which is a chimeric IgG antibody for the treatment of head and neck cancer; Vitaxin (MedImmune, Inc., MD) which is a humanized antibody for the treatment of sarcoma; Campath I/H (Leukosite, MA) which is a humanized IgG<sub>1</sub> antibody for the treatment of chronic lymphocytic leukemia (CLL); Smart MI95 (Protein Design Labs, Inc., CA) which is

a humanized IgG antibody for the treatment of acute myeloid leukemia (AML); LymphoCide (Immunomedics, Inc., NJ) which is a humanized IgG antibody for the treatment of non-Hodgkin's lymphoma; Smart I D10 (Protein Design Labs, Inc., CA) which is a humanized antibody for the treatment of non-Hodgkin's lymphoma; Oncolym  
5 (Techniclone, Inc., CA) which is a murine antibody for the treatment of non-Hodgkin's lymphoma; the monoclonal antibody 7E11 which immunospecifically binds to prostate-specific membrane antigen (PSMA; Lin et al., 1997, Cancer Res. 57:3629); and the anti-CD20 monoclonal antibody sold by Beckman Coulter, Inc., CA.

In a specific embodiment, one or more antibodies immunospecific for one or more  
10 viral or microbial antigens are administered to an animal prior to, subsequent to, or concomitantly with the administration of one or more antibodies immunospecific for C3b(i), in an amount effective for the treatment or prevention of viral or microbial infection. Examples of antibodies used for the treatment or prevention of viral or microbial infection include, but are not limited to: Synagis® (MedImmune, Inc., MD) which is a humanized  
15 anti-respiratory syncytial virus (RSV) monoclonal antibody for the treatment of patients with RSV infection; PRO542 (Progenics) which is a CD4 fusion antibody for the treatment of HIV infection; Ostavir (Protein Design Labs, Inc., CA) which is a human antibody for the treatment of hepatitis B virus; Protovir (Protein Design Labs, Inc., CA) which is a humanized IgG<sub>1</sub> antibody for the treatment of cytomegalovirus (CMV); WIN1 which  
20 immunospecifically binds to LPS (Novartis) and mouse monoclonal anti-Legionella Pneumonia LPS (Research Diagnostics, Inc. NJ).

The present invention encompasses the administration of plasma as a source of IgG and/or IgM antibodies and one or more anti-C3b(i) antibodies for the treatment or prevention of cancer, viral infection, and microbial infection. In a specific embodiment,  
25 plasma or selectively enriched IgG and/or IgM antibodies is administered to an animal, preferably a mammal and most preferably a human, prior to, subsequent to, or concomitantly with the administration of one or more anti-C3b(i) antibodies in an amount effective for the treatment or prevention of cancer, viral infection or microbial infection. The plasma or selectively enriched IgG and/or IgM antibodies may be obtained from  
30 normal animals or from animals with a particular type of cancer, a particular type viral infection, or a particular type of microbial infection.

Preferably, the plasma or selectively enriched IgG and/or IgM is obtained from an animal of the same species which receives the administration. The plasma may or may not be treated with EDTA, citrate or heparin to block the complement pathways. In a specific  
35 embodiment, plasma or selectively enriched IgG and/or IgM antibodies from an animal, which contains antibodies immunospecific for cancer cell antigens (*e.g.*, improperly glycosylated proteins or lipids) are administered to an animal prior to the administration of



anti-C3b(i) antibodies. In another specific embodiment, plasma or selectively enriched IgG and/or IgM antibodies from an animal, which contains antibodies immunospecific for a viral antigen or a microbial antigen (*e.g.*, anti-HIV gp120 antibodies or anti-LPS antibodies) are administered to an animal prior to the administration of anti-C3b(i) antibodies.

5       The present invention encompasses the administration of recombinant complement components or plasma as a source of complement components and one or more anti-C3b(i) antibodies for the treatment or prevention of cancer, viral infection, microbial infection, and septic shock. In a specific embodiment, one or more complement components or recombinant complement components are administered to an animal, preferably a mammal  
10 and most preferably a human, prior to, subsequent to, or concomitantly with the administration of antibodies immunospecific for C3b(i) in an amount effective for the treatment or prevention of cancer, viral infection, microbial infection, or septic shock. In another embodiment, normal plasma as a source of complement components is administered to an animal prior to, subsequent to, or concomitantly with the administration  
15 of antibodies immunospecific for C3b(i) in an amount effective for the treatment or prevention of cancer, viral infection, microbial infection, or septic shock.

In a specific embodiment, a source of IgG and/or IgM antibodies and complement components (*e.g.*, normal plasma) is administered to an animal to insure efficient opsonization prior to the administration of antibodies specific for C3b(i). In accordance  
20 with the invention, the administration of C3b(i) immunospecific antibodies in combination with IgG antibodies, IgM antibodies and/or complement components will initiate a chain reaction which results in increased complement activity and ultimately the killing of cancerous cells.

In a preferred embodiment, the endogenous levels of IgG antibodies, IgM antibodies  
25 and/or complement components are analyzed to determine whether an animal, preferably a mammal and most preferably a human, requires the administration of IgG antibodies, IgM antibodies and/or complement components. Standard techniques known to those of skill in the art can be utilized to measure the endogenous levels of IgG antibodies, IgM antibodies and complement components in an animal's sera. For example, the level of IgM antibodies  
30 or IgG antibodies in sera can be determined by titration of the sera against cell lines such as comparable cancer cell lines. Further, the level of complement components and complement activity can be determined by, for example, *in vitro* tests for the ability to interact with complement proteins and the ability to lyse target cells opsonized with specific antibodies (Complement: A Practical Approach, Dodds and Sim, Oxford University Press  
35 1997; Makrides et al., 1992, J. Biol. Chem. 264:24754-2476; and Weisman, H. F., et al., 1990, Science, 244:146-151). The present invention also provides compositions comprising

one or more anti-C3b(i) antibodies for use in the treatment, prevention, detection or diagnosis of cancer, viruses, and microbes.

The present invention provides methods and kits for depleting cancerous cells *in vitro* utilizing C3b(i) specific antibodies. The invention also provides methods and kits for the detection, imaging, and diagnosis of cancer utilizing antibodies specific for C3b(i). Further, the invention provides pharmaceutical compositions comprising antibodies specific for C3b(i).

### 5.1. IgG AND IgM ENRICHMENT

In accordance with certain embodiments of the present invention, the levels of IgG antibodies, IgM antibodies, and complement components in the sera or plasma of an animal are measured prior to the administration of anti-C3b(i) antibodies. In one embodiment, animals determined to have low levels of IgG antibodies and/or IgM antibodies are administered normal plasma containing IgG antibodies and/or IgM antibodies (preferably, IgG antibodies or IgM antibodies that immunospecifically bind to one or more cancer cell epitopes (*e.g.*, improperly glycosylated proteins or lipids expressed by cancer cells), viral epitopes, or microbial epitopes) prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of anti-C3b(i) antibodies for the treatment or prevention of cancer, viral infection, or microbial infection. In accordance with this embodiment, the plasma is obtained from an animal of the same species that receives the plasma. In another embodiment, animals determined to have low levels of IgM antibodies are administered plasma enriched for IgM antibodies prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of anti-C3b(i) antibodies for the treatment or prevention of cancer, viral infection, or microbial infection. In another embodiment, animals determined to have low levels of IgG antibodies are administered plasma enriched for IgG antibodies prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of anti-C3b(i) antibodies for the treatment or prevention of cancer, viral infection, or microbial infection. In accordance with these embodiments, IgM antibodies or IgG antibodies are selectively

enriched utilizing standard techniques known to those of skill in the art. Such techniques include, but are not limited to, chromatography, centrifugation, and differential solubility.

In a particular embodiment of the invention, native or recombinant IgG antibodies or IgM antibodies known to immunospecifically bind to cancer cells, viruses or microbes are administered to an animal prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of anti-C3b(i) antibodies for the treatment or prevention of cancer. IgG antibodies or IgM antibodies that immunospecifically bind to one or more cancer cell antigens (*e.g.*, improperly glycosylated proteins or lipids expressed by cancer cells), viral antigens (*e.g.*, glycoprotein F of RSV and gp120 of HIV), or microbial antigens (*e.g.*, LPS) can be purchased from a company or purified utilizing standard protein purification techniques known to those of skill in the art. Examples of standard protein purification techniques include, but are not limited to, gel purification, chromatography (*e.g.*, ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, and differential solubility. Recombinant IgG antibodies and IgM antibodies can be produced utilizing standard techniques known to those of skill in the art.

In one embodiment, plasma as a source of IgG and IgM antibodies is administered to an animal the same day as the animal is administered antibodies immunospecific for C3b(i) or C3b(i) covalently linked to a second molecule for the treatment or prevention of cancer, viral infections or microbial infections. In another embodiment, plasma as a source of IgG and IgM antibodies is administered to an animal a few minutes or hours (*e.g.*, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours) before the antibodies immunospecific for C3b(i) or C3b(i) covalently linked to a second molecule are administered to the animal for the treatment or prevention of cancer, viral infections or microbial infections.

In a preferred embodiment, IgG antibodies and/or IgM antibodies are administered to an animal the same day as the animal is administered antibodies immunospecific for C3b(i) or C3b(i) covalently linked to a second molecule for the treatment or prevention of cancer, viral infections or microbial infections. In another preferred embodiment, IgG antibodies and/or IgM antibodies are administered to an animal a few minutes or hours (*e.g.*, 5 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours or 12 hours) before administering antibodies immunospecific for C3b(i) or C3b(i) covalently linked to a second molecule for the treatment or prevention of cancer, viral infections or microbial infections.

## 5.2. COMPLEMENT COMPONENTS

In a preferred embodiment, animals determined to have low levels of complement, particularly C3, are infused with normal plasma prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of anti-C3b(i) antibodies for the treatment or prevention of cancer, viral infection, or microbial infection. In accordance with this embodiment, the plasma is obtained from an animal of the same species that receives the plasma. In another preferred embodiment, animals determined to have low levels of complement are administered native or recombinant complement proteins (*e.g.*, C3) prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of anti-C3b(i) antibodies for the treatment or prevention of cancer, viral infection, or microbial infection. In a specific embodiment, one or more complement components are administered to an animal the same day as the animal is administered anti-C3b(i) antibodies for the treatment or prevention of cancer, viral infection, or microbial infection. In another embodiment, one or more complement components are administered to an animal a few hours (*e.g.*, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours or 12 hours) before administering antibodies anti-C3b(i) antibodies for the treatment or prevention of cancer, viral infection, or microbial infection.

Complement components, in particular complement component C3, can be purchased from a company or purified utilizing standard protein purification techniques known to those of skill in the art. Examples of such purification techniques include, but are not limited to, gel purification, chromatography (*e.g.*, ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, and differential solubility. Recombinant complement components (*e.g.*, C3) can be produced utilizing standard techniques known to those of skill in the art. In accordance with the invention, the nucleic acid sequences encoding complement components can be obtained from available sequence databases, *e.g.*, GenBank. Both cDNA and genomic sequences can be cloned and expressed. Further, in accordance with the invention, the native or recombinant complement components administered to an animal for the treatment or prevention of cancer, viral infection, or microbial infection retain the ability to function in the classical and/or alternative complement pathways.

The nucleotide sequence encoding complement components or a functionally active analogs or other derivatives thereof (*e.g.*, C3) can be inserted into an appropriate expression

vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. For example, the nucleotide sequence encoding human C3 as disclosed in Genbank Accession Numbers NM\_000064 and K02765 can be inserted into an appropriate expression vector. In another example, the  
5 nucleotide sequence encoding human C1 subcomponents, human C2 or human C2 as disclosed in Genbank Accession Numbers NM\_000063, NM\_001734, J04080, and AF019413, respectively, can be inserted into an appropriate expression vector. The necessary transcriptional and translational signals can be supplied by the native complement component genes or its flanking regions. A variety of host-vector systems may be utilized  
10 to express the protein-coding sequence. These include, but are not limited to, mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); and microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on  
15 the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In specific embodiments, the human complement component genes or sequences encoding functionally active portions of the human complement components are expressed.

Any of the methods known to one of skill in the art for the insertion of DNA  
20 fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional and translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). The expression of a nucleic acid sequence encoding a complement component or fragments thereof may be  
25 regulated by a second nucleic acid sequence so that the complement component or fragments thereof are expressed in a host transformed with the recombinant DNA molecule. The expression of complement components (*e.g.*, C3) may be controlled by any promoter or enhancer element known to one of skill in the art. In particular, the expression of a complement component may regulated by any constitutive promoter, inducible promoter,  
30 tissue specific promoter, or native complement component promoter known to one of skill in the art.

Promoters which may be used to regulate the expression of a complement component (*e.g.*, C3) include, but are not limited to, viral promoters such as the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter  
35 contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. USA 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et

al., 1982, *Nature* 296:39-42); prokaryotic promoters such as the  $\beta$ -lactamase promoter (Villa-Kamaroff et al., 1978, *Proc. Natl. Acad. Sci. USA* 75:3727-3731), or the *tac* promoter (DeBoer et al., 1983, *Proc. Natl. Acad. Sci. USA* 80:21-25); see also "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94; plant

5 promoters such as the nopaline synthetase promoter region (Herrera-Estrella et al., *Nature* 303:209-213) or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., 1981, *Nucl. Acids Res.* 9:2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, *Nature* 310:115-120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol

10 dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, *Cell* 38:639-646; Ornitz et al., 1986, *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409; MacDonald, 1987, *Hepatology*

15 7:425-515), insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, *Nature* 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, *Cell* 38:647-658; Adames et al., 1985, *Nature* 318:533-538; Alexander et al., 1987, *Mol. Cell. Biol.* 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells

20 (Leder et al., 1986, *Cell* 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, *Genes and Devel.* 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, *Mol. Cell. Biol.* 5:1639-1648; Hammer et al., 1987, *Science* 235:53-58), alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, *Genes and Devel.* 1:161-171), beta-globin gene control region

25 which is active in myeloid cells (Mogam et al., 1985, *Nature* 315 :338-340; Kollias et al., 1986, *Cell* 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, *Cell* 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, *Nature* 314:283-286), and gonadotropic releasing hormone gene control region which is active in

30 the hypothalamus (Mason et al., 1986, *Science* 234:1372-1378). In certain embodiments, the promoter regulating the expression of the complement component is a constitutive promoter. In certain other embodiments, the promoter regulating the expression of the complement component is an inducible or tissue-specific promoter.

In a specific embodiment, the vector used to express a complement component

35 comprises a promoter operably linked to a complement component (*e.g.*, C3)-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (*e.g.*, an antibiotic resistance gene).

Expression vectors containing nucleotide sequences encoding one or more complement components can be identified by three general approaches: (a) nucleic acid hybridization; (b) presence or absence of "marker" gene functions; and (c) expression of inserted sequences. In the first approach, the presence of a nucleotide sequence encoding a complement component (e.g., C3) in an expression vector(s) can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to the inserted nucleotide sequence. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of the nucleotide sequence encoding the complement component in the vector(s). For example, if a nucleotide sequence encoding C3 is inserted within the marker gene sequence of the vector, recombinant vectors containing the nucleotide sequence can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying for RNA or polypeptides encoded by the nucleotide sequence for the complement component. Such assays can be based, for example, on the physical or functional properties of the complement component in *in vitro* assay systems, e.g., binding of C3 with anti-C3 antibody.

A host cell can be transfected with a nucleotide sequence encoding a complement component or a vector comprising a nucleotide sequence encoding a complement component using techniques known to those of skill in the art such as, for example, microinjection, electroporation, lipofection, and calcium phosphate precipitation. Host cells may be stably or transiently transfected with a nucleotide sequence encoding a complement component or a vector comprising a nucleotide sequence encoding a complement component.

For long-term, high-yield production of one or more recombinant complement components, stable expression is preferred. For example, cell lines which stably express one or more complement components may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes can  
 5 be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside  
 10 G-418 (Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1); and hygromycin (Santerre et al., 1984, Gene 30:147) genes.

Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. A host cell strain can be chosen which modulates the expression of the inserted sequences in the specific fashion  
 15 desired. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the complement protein expressed. Different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (*e.g.*, glycosylation and phosphorylation) of proteins. For example, expression in a bacterial system can be used to produce an unglycosylated core  
 20 protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Such mammalian host cells include, but are not limited to, 293T, CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, MT2, U937, WI38, BT483, Hs578T, HTB2, BT20, T47D, CRL7030, Hs578Bst, lymphocytes and fibroblasts. Furthermore, different vector/host  
 25 expression systems may effect processing reactions to different extents.

### 5.3. ANTIBODIES

Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, bispecific, human, humanized or chimeric antibodies, single chain antibodies, sFvs, Fab  
 30 fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above which immunospecifically bind to cancer cell antigens, viral antigens, microbial antigens, C3b(i) or fragments thereof, or C3b(i) linked to a second molecule. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of  
 35 immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which immunospecifically binds a cancer cell antigen, a viral antigen, a microbial antigen, C3b(i), or C3b(i) linked (*e.g.*, covalently linked) to a second molecule. The immunoglobulin



molecules of the invention can be of any type (*e.g.*, IgG, IgE, IgM, IgD and IgA ), class, or subclass of immunoglobulin molecule.

Polyclonal antibodies which may be used in the methods of the invention are heterogeneous populations of antibody molecules derived from the sera of immunized  
5 animals. Various procedures well known in the art may be used for the production of polyclonal antibodies to an antigen-of-interest. For example, for the production of polyclonal antibodies, various host animals can be immunized by injection with an antigen of interest or derivative thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host  
10 species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

15 Monoclonal antibodies which may be used in the methods of the invention are homogeneous populations of antibodies to a particular antigen (*e.g.*, a cancer cell antigen, a viral antigen, a microbial antigen, C3b(i) or C3b(i) covalently linked to a second molecule). A monoclonal antibody (mAb) to an antigen-of-interest can be prepared by using any technique known in the art which provides for the production of antibody molecules by  
20 continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256, 495-497), the more recent human B cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4: 72), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any  
25 immunoglobulin class including IgG, IgM, IgE, IgA, and IgD and any subclass thereof. The hybridoma producing the mAbs of use in this invention may be cultivated *in vitro* or *in vivo*.

The monoclonal antibodies which may be used in the methods of the invention include, but are not limited to, human monoclonal antibodies or chimeric human-mouse (or  
30 other species) monoclonal antibodies. Human monoclonal antibodies may be made by any of numerous techniques known in the art (*e.g.*, Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80, 7308-7312; Kozbor et al., 1983, Immunology Today 4, 72-79; and Olsson et al., 1982, Meth. Enzymol. 92, 3-16).

The invention further provides for the use of bispecific antibodies. Methods for  
35 making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Milstein et al., 1983, Nature

305:537-539). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low.

Similar procedures are disclosed in PCT Publication No. WO 93/08829, published 13 May 1993, and in Traunecker et al., 1991, EMBO J. 10:3655-3659 .

According to a different and more preferred approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance.

In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in PCT Publication No. WO 94/04690 published March 3, 1994, which is incorporated herein by reference in its entirety.

For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 1986, 121:210. Using such techniques, a bispecific molecule which combines anti-C3b(i) antibody and an antibody specific for an effector cell receptor or antigen can be prepared for use in the treatment or inhibition of disease as defined herein.

The invention provides for the use of functionally active fragments, derivatives or analogs of antibodies which immunospecifically bind to cancer cell antigens, viral antigens, and microbial antigens. Functionally active means that the fragment, derivative or analog is

able to elicit anti-anti-idiotypic antibodies that recognize the same antigen that the antibody from which the fragment, derivative or analog is derived recognized. Specifically, in a preferred embodiment the antigenicity of the idiotype of the immunoglobulin molecule may be enhanced by deletion of framework and CDR sequences that are C-terminal to the CDR  
5 sequence that specifically recognizes the antigen. To determine which CDR sequences bind the antigen, synthetic peptides containing the CDR sequences can be used in binding assays with the antigen by any binding assay method known in the art (*e.g.*, the BIA core assay)

Other embodiments of the invention include fragments of the antibodies of the invention such as, but not limited to, F(ab')<sub>2</sub> fragments, which contain the variable region,  
10 the light chain constant region and the CH1 domain of the heavy chain can be produced by pepsin digestion of the antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. The invention also provides heavy chain and light chain dimers of the antibodies of the invention, or any minimal fragment thereof such as Fvs or single chain antibodies (SCAs) (*e.g.*, as described in U.S. Patent  
15 4,946,778; Bird, 1988, Science 242:423-42; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-54), or any other molecule with the same specificity as the antibody of the invention.

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using  
20 standard recombinant DNA techniques, are within the scope of the invention. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine monoclonal and a human immunoglobulin constant region. (See, *e.g.*, Cabilly et al., U.S. Patent No. 4,816,567; and Boss et al., U.S. Patent No. 4,816,397, which are incorporated herein by reference in their  
25 entirety.) Humanized antibodies are antibody molecules from non-human species having one or more complementarily determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, *e.g.*, Queen, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA  
30 techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Patent No. 4,816,567; European Patent Application 125,023; Better et al., 1988, Science 240:1041-1043; Liu et al., 1987, Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al.,  
35 1987, J. Immunol. 139:3521-3526; Sun et al., 1987, Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al., 1987, Canc. Res. 47:999-1005; Wood et al., 1985, Nature 314:446-449; and Shaw et al., 1988, J. Natl. Cancer Inst. 80:1553-1559; Morrison, 1985, Science

229:1202-1207; Oi et al., 1986, Bio/Techniques 4:214; U.S. Patent 5,225,539; Jones et al., 1986, Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al., 1988, J. Immunol. 141:4053-4060; each of which is incorporated herein by reference in its entirety.

5 Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, *e.g.*, all or a portion of a polypeptide of the  
10 invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this  
15 technology for producing human antibodies, see Lonberg and Huszar (1995, Int. Rev. Immunol. 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, *see, e.g.*, U.S. Patent 5,625,126; U.S. Patent 5,633,425; U.S. Patent 5,569,825; U.S. Patent 5,661,016; and U.S. Patent 5,545,806; each of which is incorporated herein by reference in  
20 its entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human  
25 monoclonal antibody, *e.g.*, a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al. (1994) Bio/technology 12:899-903).

In other embodiments, the invention provides fusion proteins of the antibodies of the invention (or functionally active fragments thereof), for example in which the antibody is  
30 fused via a covalent bond (*e.g.*, a peptide bond), at either the N-terminus or the C-terminus to an amino acid sequence of another protein (or portion thereof, preferably at least 10, 20 or 50 amino acid portion of the protein) that is not the antibody. Preferably, the antibody or fragment thereof is covalently linked to the other protein at the N-terminus of the constant domain.

35 The antibodies of the invention include analogs and derivatives that are either modified, *i.e.*, by the covalent attachment of any type of molecule as long as such covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For

example, but not by way of limitation, the derivatives and analogs of the antibodies include those that have been further modified, *e.g.*, by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical  
5 modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the analog or derivative may contain one or more non-classical amino acids.

The antibodies of the invention include antibodies with modifications (*e.g.*,  
10 substitutions, deletions or additions) in amino acid residues that interact with Fc receptors. In particular, the antibodies of the invention include antibodies with modifications in amino acid residues identified as involved in the interaction between the Fc domain and the FcRn receptor (see, *e.g.*, PCT Publication No. WO 97/34631, which is incorporated herein by reference in its entirety).

15

### 5.3.1. ANTI-C3b(i) ANTIBODIES

In a specific embodiment, anti-C3b(i) antibodies are immunospecific for C3b(i) or a fragment thereof (*e.g.*, at least 5, at least 10, at least 15, at least 25, or more contiguous amino acid residues of C3b(i)). In another embodiment, anti-C3b(i) antibodies are  
20 immunospecific for C3b(i) covalently linked to a second molecule. In a preferred embodiment, anti-C3b(i) antibodies are monoclonal antibodies or Fab fragments. In another preferred embodiment, anti-C3b(i) antibodies are immunospecific for C3b(i) bound to IgG or IgM antibodies and said anti-C3b(i) antibodies have minimal cross-reactivity with C3b(i) in the media or milieu. In another preferred embodiment, anti-C3b(i) antibodies are  
25 immunospecific for C3b(i) bound to a cancer cell or C3b(i) bound to a virus or microbe; and said anti-C3b(i) antibodies have minimal cross-reactivity with C3b(i) in the media or milieu. In yet another preferred embodiment, anti-C3b(i) antibodies administered to humans are humanized or human monoclonal antibodies.

Anti-C3b(i) antibodies can be obtained from any organization (*e.g.*, a university  
30 scientist or a company such as Research Diagnostics Inc. in New Jersey) or produced by any method known to one of skill in the art. For example, anti-C3b(i) antibodies can be produced by chemical synthesis or recombinant expression techniques. The nucleotide sequence encoding an anti-C3b(i) antibodies can be obtained, *e.g.*, from the GenBank database or a database like it, the literature publications, or by routine cloning and  
35 sequencing.

In one embodiment, an anti-C3b(i) antibody is monoclonal antibody 7C12, 2H11, 8E11 or 3E7 (see, *e.g.*, Ferguson et al., 1995, *Arthritis Rheum.* 38:190; Taylor et al., 1989,

J. Immunology 143:3626; Tosic et al., 1989, J. Immunol. Methods 120:241; and Sokoloff et al., 2000, Cancer Immunol. Immunother. 49:551-562, each of which is incorporated herein by reference in their entirety). In another embodiment, an anti-C3b(i) antibody is an antibody that competes with 7C12, 2H11, 8E11 or 3E7 for binding to C3b(i) or a fragment thereof, as determined by an immunoassay such as, *e.g.*, an ELISA. In a preferred embodiment, an anti-C3b(i) antibody is monoclonal antibody 3E7. In another preferred embodiment, an anti-C3b(i) antibody is an antibody that competes with monoclonal 3E7 for binding to C3b(i) or a fragment thereof, as determined by an immunoassay such as, *e.g.*, an ELISA. In yet another preferred embodiment, an anti-C3b(i) antibody is a bispecific monoclonal antibody comprising monoclonal antibody 3E7 and monoclonal antibody 7G9 (see, *e.g.*, Sokoloff et al., 2000, Cancer Immunol. Immunother. 49:551-562).

### 5.3.2. ANTIBODIES IMMUNOSPECIFIC FOR CANCER CELLS

In a specific embodiment, antibodies immunospecific for a cancer cell antigen for use in accordance with methods of the invention are monoclonal antibodies or Fab fragments. Preferably, antibodies immunospecific for a cancer cell antigen which are administered to humans are humanized or human monoclonal antibodies. As used herein, the term "cancer cell antigen" refers to an antigen (*e.g.*, a protein, glycoprotein, polypeptide, peptide, or glycolipid) that is preferentially or differentially expressed on cancer cells relative to non-cancerous cells, preferably normal cells. Examples of cancer cell antigens include, but are not limited, to improperly glycosylated proteins and lipids, CD20, Her-2, and PSMA.

Antibodies immunospecific for a cancer cell antigen can be obtained from any organization (*e.g.*, a university scientist or a company such as Genentech) or produced by any method known to one of skill in the art such as, *e.g.*, chemical synthesis or recombinant expression techniques. The nucleotide sequence encoding antibodies immunospecific for a cancer cell antigen can be obtained, *e.g.*, from the GenBank database or a database like it, the literature publications, or by routine cloning and sequencing.

In a specific embodiment, known antibodies for the treatment or prevention cancer are used in accordance with the methods of the invention. Examples of antibodies available for the treatment of cancer include, but are not limited to, Herceptin® (Trastuzumab; Genentech, CA) which is a humanized anti-HER2 monoclonal antibody for the treatment of patients with metastatic breast cancer; Retuxan® (rituximab; Genentech) which is a chimeric anti-CD20 monoclonal antibody for the treatment of patients with non-Hodgkin's lymphoma; OvaRex (AltaRex Corporation, MA) which is a murine antibody for the treatment of ovarian cancer; Panorex (Glaxo Wellcome, NC) which is a murine IgG<sub>2a</sub>

antibody for the treatment of colorectal cancer; BEC2 (ImClone Systems Inc., NY) which is murine IgG antibody for the treatment of lung cancer; IMC-C225 (Imclone Systems Inc., NY) which is a chimeric IgG antibody for the treatment of head and neck cancer; Vitaxin (MedImmune, Inc., MD) which is a humanized antibody for the treatment of sarcoma; 5 Campath I/H (Leukosite, MA) which is a humanized IgG<sub>1</sub> antibody for the treatment of chronic lymphocytic leukemia (CLL); Smart MI95 (Protein Design Labs, Inc., CA) which is a humanized IgG antibody for the treatment of acute myeloid leukemia (AML); LymphoCide (Immunomedics, Inc., NJ) which is a humanized IgG antibody for the treatment of non-Hodgkin's lymphoma; Smart I D10 (Protein Design Labs, Inc., CA) which 10 is a humanized antibody for the treatment of non-Hodgkin's lymphoma; and Oncolym (Techniclone, Inc., CA) which is a murine antibody for the treatment of non-Hodgkin's lymphoma.

### 5.3.3. ANTIBODIES TO VIRAL AND MICROBIAL ANTIGENS

15 In a specific embodiment, antibodies immunospecific for a viral or microbial antigen for use in accordance with methods of the invention are monoclonal antibodies. Preferably, antibodies immunospecific for a viral antigen or microbial antigen which are administered to humans are humanized or human monoclonal antibodies. As used herein, the term "viral antigen" includes, but is not limited to, any viral peptide, polypeptide protein 20 (e.g., HIV gp120, HIV nef, RSV F glycoprotein, influenza virus neuraminidase, influenza virus hemagglutinin, HTLV tax, herpes simplex virus glycoprotein (e.g., gB, gC, gD, and gE) and hepatitis B surface antigen) which is capable of eliciting an immune response. As used herein, the term "microbial antigen" includes, but is not limited to, any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule (e.g., a bacterial, 25 fungi, pathogenic protozoa, or yeast polypeptide including, e.g., LPS and capsular polysaccharide 5/8) which is capable of eliciting an immune response.

Antibodies immunospecific for a viral or microbial antigen can be obtained from any organization (e.g., a university scientist or a company such as Genentech) or produced by any method known to one of skill in the art such as, e.g., chemical synthesis or 30 recombinant expression techniques. The nucleotide sequence encoding antibodies immunospecific for a viral or microbial antigen can be obtained, e.g., from the GenBank database or a database like it, the literature publications, or by routine cloning and sequencing.

35 In a specific embodiment, known antibodies for the treatment or prevention viral or microbial infection are used in accordance with the methods of the invention. Examples of antibodies available for the treatment of viral infection or microbial infection include, but are not limited to, Synagis® (MedImmune, Inc., MD) which is a humanized anti-respiratory

syncytial virus (RSV) monoclonal antibody for the treatment of patients with RSV infection; PRO542 (Progenics) which is a CD4 fusion antibody for the treatment of HIV infection; Ostavir (Protein Design Labs, Inc., CA) which is a human antibody for the treatment of hepatitis B virus; Protovir (Protein Design Labs, Inc., CA) which is a  
5 humanized IgG<sub>1</sub> antibody for the treatment of cytomegalovirus (CMV); and anti-LPS antibodies.

#### 5.4. PRODUCTION OF RECOMBINANT ANTIBODIES

The antibodies of the invention can be produced by any method known in the art for  
10 the synthesis of antibodies, in particular, by chemical synthesis or by recombinant expression, and are preferably produced by recombinant expression techniques.

Recombinant expression of the antibodies of the invention, or fragment, derivative or analog thereof, requires construction of a nucleic acid that encodes the antibody. If the nucleotide sequence of the antibody is known, a nucleic acid encoding the antibody may be  
15 assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., 1994, *BioTechniques* 17:242), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligation of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a nucleic acid molecule encoding an antibody may be generated from  
20 a suitable source. If a clone containing the nucleic acid encoding the particular antibody is not available, but the sequence of the antibody is known, a nucleic acid encoding the antibody may be obtained from a suitable source (e.g., an antibody cDNA library, or cDNA library generated from any tissue or cells expressing the immunoglobulin) by PCR  
25 amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence.

If an antibody that specifically recognizes a particular antigen is not available (or a source for a cDNA library for cloning a nucleic acid encoding such an immunoglobulin), antibodies specific for a particular antigen may be generated by any method known in the  
30 art, for example, by immunizing an animal, such as a rabbit, to generate polyclonal antibodies or, more preferably, by generating monoclonal antibodies, e.g., as described by Kohler and Milstein (1975, *Nature* 256:495-497) or, as described by Kozbor et al. (1983, *Immunology Today* 4:72) or Cole et al. (1985 in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Alternatively, a clone encoding at least the Fab  
35 portion of the antibody may be obtained by screening Fab expression libraries (e.g., as described in Huse et al., 1989, *Science* 246:1275-1281) for clones of Fab fragments that



bind the specific antigen or by screening antibody libraries (See, *e.g.*, Clackson et al., 1991, *Nature* 352:624; Hane et al., 1997 *Proc. Natl. Acad. Sci. USA* 94:4937).

Once a nucleic acid sequence encoding at least the variable domain of the antibody is obtained, it may be introduced into a vector containing the nucleotide sequence encoding the constant regions of the antibody (see, *e.g.*, PCT Publication No. WO 86/05807; PCT Publication No. WO 89/01036; and U.S. Patent No. 5,122,464). Vectors containing the complete light or heavy chain that allow for the expression of a complete antibody molecule are available. Then, the nucleic acid encoding the antibody can be used to introduce the nucleotide substitutions or deletion necessary to substitute (or delete) the one or more variable region cysteine residues participating in an intrachain disulfide bond with an amino acid residue that does not contain a sulfhydryl group. Such modifications can be carried out by any method known in the art for the introduction of specific mutations or deletions in a nucleotide sequence, for example, but not limited to, chemical mutagenesis and *in vitro* site directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem.* 253:6551).

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, *Proc. Natl. Acad. Sci.* 81:851-855; Neuberger et al., 1984, *Nature* 312:604-608; Takeda et al., 1985, *Nature* 314:452-454) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described *supra*, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region, *e.g.*, humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,694,778; Bird, 1988, *Science* 242:423-42; Huston et al., 1988, *Proc. Natl. Acad. Sci. USA* 85:5879-5883; and Ward et al., 1989, *Nature* 334:544-54) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in *E. coli* may also be used (Skerra et al., 1988, *Science* 242:1038-1041).

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')<sub>2</sub> fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments.

Once a nucleic acid sequence encoding an antibody of the invention has been obtained, the vector for the production of the antibody may be produced by recombinant DNA technology using techniques well known in the art. Methods which are well known to

those skilled in the art can be used to construct expression vectors containing the antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. See, for example, the techniques described in Sambrook  
5 et al. (1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) and Ausubel et al. (eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY).

An expression vector comprising the nucleotide sequence of an antibody or the nucleotide sequence of an antibody can be transferred to a host cell by conventional  
10 techniques (e.g., electroporation, liposomal transfection, and calcium phosphate precipitation) and the transfected cells are then cultured by conventional techniques to produce the antibody of the invention. In specific embodiments, the expression of the antibody is regulated by a constitutive, an inducible or a tissue, specific promoter.

The host cells used to express the recombinant antibody of the invention may be  
15 either bacterial cells such as *Escherichia coli*, or, preferably, eukaryotic cells, especially for the expression of whole recombinant immunoglobulin molecule. In particular, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for immunoglobulins (Foecking et al., 198, Gene 45:101;  
20 Cockett et al., 1990, Bio/Technology 8:2).

A variety of host-expression vector systems may be utilized to express the immunoglobulin molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of the antibody may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the  
25 appropriate nucleotide coding sequences, express the immunoglobulin molecule of the invention *in situ*. These include, but are not limited to, microorganisms such as bacteria (e.g., *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing immunoglobulin coding sequences; yeast (e.g., *Saccharomyces Pichia*) transformed with recombinant yeast expression vectors  
30 containing immunoglobulin coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the immunoglobulin coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing  
35 immunoglobulin coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 293T, 3T3 cells) harboring recombinant expression constructs containing promoters

derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody being expressed. For example, 5 when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the antibody coding sequence may be ligated individually into 10 the vector in frame with the *lac Z* coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, *Nucleic Acids Res.* 13:3101-3109; Van Heeke & Schuster, 1989, *J. Biol. Chem.* 24:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by 15 adsorption and binding to a matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is 20 used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be 25 utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a 30 recombinant virus that is viable and capable of expressing the immunoglobulin molecule in infected hosts. (e.g., see Logan & Shenk, 1984, *Proc. Natl. Acad. Sci. USA* 81:355-359). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired 35 coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate

transcription enhancer elements, transcription terminators, etc. (see Bittner et al., 1987, *Methods in Enzymol.* 153:51-544).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.

10 To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 293T, 3T3, WI38, BT483, Hs578T, HTB2, BT20 and T47D, CRL7030 and Hs578Bst.

15 For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express an antibody may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a

20 selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may

25 advantageously be used to engineer cell lines which express the antibody. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., 1977, *Cell* 11:223), hypoxanthine-guanine

30 phosphoribosyltransferase (Szybalska & Szybalski, 192, *Proc. Natl. Acad. Sci. USA* 48:202), and adenine phosphoribosyltransferase (Lowy et al., 1980, *Cell* 22:817) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, *Natl. Acad. Sci. USA* 77:357; O'Hare et al., 1981, *Proc.*

35 *Natl. Acad. Sci. USA* 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072); neo, which confers resistance to the aminoglycoside G-418 *Clinical Pharmacy* 12:488-505; Wu and Wu, 1991,

- Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May, 1993, TIB TECH 11(5):155-215). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY; and in Chapters 12 and 13, Dracopoli et al. (eds), 1994, Current Protocols in Human Genetics, John Wiley & Sons, NY.; Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1; and hygromycin, which confers resistance to hygromycin (Santerre et al., 1984, Gene 30:147).
- 10        The expression levels of an antibody can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing an antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the
- 15        number of copies of the marker gene. Since the amplified region is associated with the nucleotide sequence of the antibody, production of the antibody will also increase (Crouse et al., 1983, Mol. Cell. Biol. 3:257).

      The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a

20        light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, 1986, Nature 322:52; Kohler, 1980, Proc. Natl. Acad.

25        Sci. USA 77:2197). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

      Once the antibody has been recombinantly expressed, it may be purified by any method known in the art for purification of an antibody, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A,

30        and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.

### 5.5. ANTIBODY CONJUGATES

In certain embodiments, one or more antibodies immunospecific for one or more cancer cell antigens, viral antigens or microbial antigens are conjugated to a therapeutic agent. In a preferred embodiment, anti-C3b(i) antibodies are conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, *e.g.*, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. See generally U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .

Further, an antibody may be conjugated to a therapeutic moiety such as a cytotoxin, *e.g.*, a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (*e.g.*, mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, mithramycin, anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine and vinblastine).

In one embodiment, anti-C3b(i) antibodies are conjugated to cobra venom factor. In accordance with the invention, C3b(i) specific antibodies conjugated to cobra venom factor are utilized *in vitro* to deplete cancerous cells from, *e.g.*, bone marrow obtained from an animal, preferably a mammal and most preferably a human, with cancer. Methods of  
5 conjugating antibodies to cobra venom factor are taught in U.S. Patent No. 5,773,243, which is incorporated herein by reference in its entirety.

The conjugates of the invention can be used for modifying a given biological response; thus, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or  
10 polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon,  $\gamma$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, a thrombotic agent or an anti-angiogenic agent, *e.g.*, angiostatin or endostatin; or, biological response modifiers such  
15 as, for example, lymphokines, IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-15, granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Techniques for conjugating therapeutic moieties to antibodies are well known, see, *e.g.*, Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer  
20 Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp.  
25 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982); each of which is incorporated herein by reference.

30 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference.

An antibody with or without a therapeutic moiety conjugated to it can be used as a therapeutic and administered alone or in combination with cytotoxic factor(s) and/or  
35 cytokine(s).

### 5.6. DEPLETION OF CANCEROUS CELLS *IN VITRO*

The invention provides for methods of depleting cancerous cells from non-cancerous tissues and/or cells *in vitro* (or *ex vivo*). In particular, the invention provides for methods of depleting cancerous cells by killing them or by separating them from non-cancerous cells.

- 5 In one embodiment, anti-C3b(i) antibodies alone or in combination with plasma, are combined *in vitro* with tissues and/or cells obtained from an animal, preferably a mammal and most preferably a human. In another embodiment, anti-C3b(i) antibodies alone or in combination with IgG antibodies, IgM antibodies and/or one or more complement components, are combined *in vitro* with tissues and/or cells obtained from an animal,
- 10 preferably a mammal and most preferably a human. In another embodiment, anti-C3b(i) antibodies alone or in combination with antibodies immunospecific for cancer cell antigens are combined *in vitro* with tissues and/or cells obtained from an animal, preferably a mammal and most preferably a human. Preferably, the tissue obtained from an animal for the *in vitro* depletion of cancerous cells from non-cancerous cells is bone marrow and /or
- 15 peripheral blood.

In a specific embodiment, monoclonal antibodies immunospecific for C3b(i) are incubated *in vitro* with tissues and/or cells obtained from an animal, preferably a mammal and most preferably a human. In a preferred embodiment, the monoclonal antibodies are immunospecific for C3b(i) covalently linked to IgM or IgG antibody which is bound to the

20 cancer cells. In another preferred embodiment, the monoclonal antibodies are immunospecific for C3b(i) covalently linked to a glycoprotein or or glycolipid on the cancer cells, CD20, Her2 or PSMA.

In a preferred embodiment, bispecific antibodies which are immunospecific for C3b(i) and an effector cell receptor or antigen are incubated *in vitro* with tissues and/or cells

25 obtained from an animal, preferably a mammal and most preferably a human. In another preferred embodiment, bispecific antibodies which are immunospecific for C3b(i) and a complement component (*e.g.*, C1q) are incubated *in vitro* with tissues and/or cells obtained from an animal, preferably a mammal and most preferably a human. In a particular embodiment, bispecific diabodies which are antibodies fragments immunospecific for

30 C3b(i) and a complement component (*e.g.*, C1q) are incubated *in vitro* with tissues and/or cells obtained from an animal, preferably a mammal and most preferably a human. In accordance with this embodiment, the bispecific diabodies facilitate complement mediated lysis of the cancer cells.

In accordance with the invention, the anti-C3b(i) antibodies used in the *in vitro*

35 depletion of cancer cells from tissues can be conjugated to detectable substances (*e.g.*, various enzymes, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials) or therapeutic agents (*e.g.*, cytostatic and cytotoxic agents), which



are disclosed in section 5.5. For example, anti-C3b(i) antibodies may be conjugated to cobra venom factor in order to use enhanced complement activation to lyse the cancer cells. In a specific embodiment, tissues and/or cells thus depleted of cancerous cells are administered to an animal, preferably a mammal and most preferably a human. In a preferred embodiment, the tissues and/or cells are obtained from an animal with cancer prior to treatment for cancer, and tissues and/or cells depleted of cancerous cells are administered to the animal after the treatment. In yet another preferred embodiment, the *in vitro* depletion of cancerous cells using anti-C3b(i) antibodies is done prior to administration of autologous bone marrow peripheral blood, or peripheral blood stem cells.

Anti-C3b(i) antibodies conjugated to detectable substances can be utilized to sort cancerous cells from non-cancerous cells by methods known to those of skill in the art. In one embodiment, cancerous cells are sorted using a fluorescence activated cell sorter (FACS). Fluorescence activated cell sorting (FACS) is a well-known method for separating particles, including cells, based on the fluorescent properties of the particles (Kamarch, 1987, Methods Enzymol, 151:150-165). Laser excitation of fluorescent moieties in the individual particles results in a small electrical charge allowing electromagnetic separation of positive and negative particles from a mixture.

In one embodiment, cells, particularly bone marrow cells or peripheral blood stem cells, obtained from an animal, preferably a mammal and most preferably a human, are incubated with fluorescently labeled C3b(i) specific antibodies for a time sufficient to allow the labeled antibodies to bind to the cells (*e.g.*, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes or more), preferably between 10 to 60 minutes. In an alternative embodiment, cells, particularly bone marrow cells or peripheral blood stem cells, obtained from an animal preferably a mammal and most preferably a human, are incubated with C3b(i) specific antibodies, the cells are washed, and the cells are incubated with a second labeled antibody that recognizes the C3b(i) specific antibodies. In accordance with these embodiments, the cells are washed and processed through the cell sorter, allowing separation of cells that bind both antibodies to be separated from hybrid cells that do not bind both antibodies. FACS sorted particles may be directly deposited into individual wells of 96-well or 384-well plates to facilitate separation.

In another embodiment, magnetic beads can be used to separate cancerous cells from non-cancerous cells. Cancerous cells may be sorted using a magnetic activated cell sorting (MACS) technique, a method for separating particles based on their ability to bind magnetic beads (0.5-100 nm diameter) (Dynal, 1995). A variety of useful modifications can be performed on the magnetic microspheres, including covalent addition of antibody which immunospecifically recognizes C3b(i). A magnetic field is then applied, to physically

manipulate the selected beads. The beads are then mixed with the cells to allow binding. Cells are then passed through a magnetic field to separate out cancerous cells.

#### 5.7. THERAPEUTIC AND PROPHYLACTIC USE OF ANTI-C3b(i) ANTIBODIES

5 The invention provides for treatment or prevention of cancer, including, but not limited to, neoplasms, tumors, metastases, or any disease or disorder characterized by uncontrolled cell growth, by the administration of therapeutically or prophylactically effective amounts of anti-C3b(i) antibodies or nucleic acid molecules encoding said  
10 antibodies. Examples of types of cancer and proliferative disorders include, but are not limited to, leukemia (*e.g.*, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic myelocytic (granulocytic) leukemia, and chronic lymphocytic leukemia), lymphoma (*e.g.*, Hodgkin's disease and non-Hodgkin's disease), fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma,  
15 endotheliosarcoma, Ewing's tumor, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hepatoma, Wilms' tumor, cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, oligodendroglioma, melanoma, neuroblastoma, retinoblastoma, dysplasia and hyperplasia. In a particular embodiment, therapeutic  
20 compounds of the invention are administered to men with prostate cancer (*e.g.*, prostatitis, benign prostatic hypertrophy, benign prostatic hyperplasia (BPH), prostatic paraganglioma, prostate adenocarcinoma, prostatic intraepithelial neoplasia, prostatic fistulas, and atypical prostatic stromal lesions). The treatment and/or prevention of cancer includes, but  
25 is not limited to, alleviating one or more symptoms associated with cancer, the inhibition or reduction of the progression of cancer, the promotion of the regression of cancer, and/or the promotion of the immune response. In one embodiment, commercially available or naturally occurring anti-C3b(i) antibodies, functionally active fragments or derivatives thereof are used in the present invention.

30 In certain embodiments, a composition of the invention is administered to an animal to ameliorate one or more symptoms associated with cancer. In certain other embodiments, a composition of the invention is administered to an animal to inhibit or reduce the progression of cancer. In certain other embodiments, a composition of the invention is administered to an animal to promote the regression of cancer.

35 In a specific embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies is administered to an animal in order to ameliorate one or more symptoms associated with cancer. In another embodiment, a

composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies is administered to an animal in order to promote of the regression of cancer and/or the inhibit or reduce the progression of cancer in an animal. In another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more cancer cell antigens is administered to an animal in order to ameliorate one or more symptoms associated with cancer. In yet another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more cancer cell antigens is administered to an animal in order to promote of the regression of cancer and/or the inhibit or reduce the progression of cancer in an animal.

Anti-C3b(i) antibodies may be administered alone or in combination with other types of cancer treatments (*e.g.*, radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Examples of anti-tumor agents include, but are not limited to, cisplatin, ifosfamide, paclitaxel, taxanes, topoisomerase I inhibitors (*e.g.*, CPT-11, topotecan, 9-AC, and GG-211), gemcitabine, vinorelbine, oxaliplatin, 5-fluorouracil (5-FU), leucovorin, vinorelbine, temodal, and taxol. In one embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, after surgical resection of cancer. In another embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, in conjugation with chemotherapy or radiotherapy. In another embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of cancer prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of plasma to the animal.

In a preferred embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of cancer prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of IgG antibodies, IgM antibodies and/or one or more complement components to the animal. In another preferred embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8

hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of antibodies immunospecific for one or more cancer cell antigens. In yet another preferred embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of cancer prior to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of antibodies currently used for the treatment of cancer. Examples of such antibodies include, but are not limited to, Herceptin®, Retuxan®, OvaRex, Panorex, BEC2, IMC-C225, Vitaxin, Campath I/H, Smart MI95, LymphoCide, Smart I D10, and Oncolym.

In a specific embodiment, men with prostate cancer are administered anti-C3b(i) antibodies in conjugation with androgen ablation therapy. In another specific embodiment, non-Hodgkin's lymphoma patients are treated with Retuxan® prior to the administration of anti-C3b(i) antibodies. In certain embodiments, animals with increased risk of cancer are administered a composition of the invention. Examples of such animals include, but are not limited to, humans prone to breast cancer.

The invention provides methods for the treatment or prevention of viral infections in an animal, preferably a mammal and most preferably a human, said methods comprising the administration of a therapeutically or prophylactically effective amount of anti-C3b(i) antibodies or nucleic acid molecules encoding said antibodies. Examples of viral infections which can be treated or prevented in accordance with this invention include, but are limited to, viral infections caused by retroviruses (e.g., human T-cell lymphotropic virus (HTLV) types I and II and human immunodeficiency virus (HIV)), herpes viruses (e.g., herpes simplex virus (HSV) types I and II, Epstein-Barr virus and cytomegalovirus), arenaviruses (e.g., lassa fever virus), paramyxoviruses (e.g., morbillivirus virus, human respiratory syncytial virus, and pneumovirus), adenoviruses, bunyaviruses (e.g., hantavirus), coronaviruses, filoviruses (e.g., Ebola virus), flaviviruses (e.g., hepatitis C virus (HCV), yellow fever virus, and Japanese encephalitis virus), hepadnaviruses (e.g., hepatitis B viruses (HBV)), orthomyoviruses (e.g., Sendai virus and influenza viruses A, B and C), papovaviruses (e.g., papillomaviruses), picornaviruses (e.g., rhinoviruses, enteroviruses and hepatitis A viruses), poxviruses, reoviruses (e.g., rotaviruses), togaviruses (e.g., rubella virus), and rhabdoviruses (e.g., rabies virus). The treatment and/or prevention of a viral infection includes, but is not limited to, alleviating one or more symptoms associated with

said infection, the inhibition, reduction or suppression of viral replication, and/or the enhancement of the immune response.

In certain embodiments, a composition of the invention is administered to an animal to ameliorate one or more symptoms associated with a viral infection or a disease or disorder resulting, directly or indirectly, from a viral infection. In a specific embodiment, a composition of the invention is administered to a human to ameliorate one or more symptoms associated with AIDS. In certain other embodiments, a composition of the invention is administered to reduce the titer of a virus in an animal. In certain other embodiments, a composition of the invention is administered to an animal to enhance or promote the immune response.

In a specific embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies is administered to an animal in order to ameliorate one or more symptoms associated with a viral infection. In another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies is administered to an animal in order to reduce the titer of a virus in an animal. In another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more viral antigens is administered to an animal in order to ameliorate one or more symptoms associated with a viral infection. In yet another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more viral antigens is administered to an animal in order to reduce the titer of a virus in an animal.

Anti-C3b(i) antibodies may be administered alone or in combination with other types of anti-viral agents. Examples of anti-viral agents include, but are not limited to: cytokines (*e.g.*, IFN- $\alpha$ , IFN- $\beta$ , and IFN- $\gamma$ ); inhibitors of reverse transcriptase (*e.g.*, AZT, 3TC, D4T, ddC, ddI, d4T, 3TC, adefovir, efavirenz, delavirdine, nevirapine, abacavir, and other dideoxynucleosides or dideoxyfluoronucleosides); inhibitors of viral mRNA capping, such as ribavirin; inhibitors of proteases such HIV protease inhibitors (*e.g.*, amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir,); amphotericin B; castanospermine as an inhibitor of glycoprotein processing; inhibitors of neuraminidase such as influenza virus neuraminidase inhibitors (*e.g.*, zanamivir and oseltamivir); topoisomerase I inhibitors (*e.g.*, camptothecins and analogs thereof); amantadine; and rimantadine. Such anti-viral agents may be administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of a viral infection prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1

hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of anti-C3b(i) antibodies to the animal.

In a specific embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of a viral infection prior to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of plasma to the animal.

In a preferred embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of a viral infection prior to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of IgG antibodies, IgM antibodies and/or one or more complement components to the animal. In another preferred embodiment, anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of a viral infection prior to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of antibodies immunospecific for one or more viral antigens. Example of antibodies immunospecific for viral antigens include, but are not limited to, Synagis®, PRO542, Ostavir, and Protovir.

The invention provides methods for the treatment or prevention of microbial infections in an animal, preferably a mammal and most preferably a human, said methods comprising the administration of a therapeutically or prophylactically effective amount of anti-C3b(i) antibodies or nucleic acid molecules encoding said antibodies. Examples of microbial infections which can be treated or prevented in accordance with this invention include, but are not limited to, yeast infections, fungal infections, protozoan infections and bacterial infections. Bacteria which cause microbial infections include, but are not limited to, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter (Vibrio) fetus*, *Campylobacter jejuni*,

*Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Treponema pallidum*, *Treponema pertenu*, *Treponema carateneum*, *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira*  
 5 *icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma spp.*, *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia spp.*, and *Helicobacter pylori*. The treatment and/or prevention of a microbial infection includes, but is not limited to, alleviating one or more symptoms associated with said infection, the  
 10 inhibition, reduction or suppression of microbial replication, and/or the enhancement of the immune response.

In certain embodiments, a composition of the invention is administered to an animal to ameliorate one or more symptoms associated with a microbial infection or a disease or disorder resulting, directly or indirectly, from a microbial infection. In certain other  
 15 embodiments, a composition of the invention is administered to reduce the number or microbes in an animal.

In a specific embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies is administered to an animal in order to ameliorate one or more symptoms associated with a microbial infection. In another  
 20 embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies is administered to an animal in order to reduce the number of microbes in an animal. In another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more microbial antigens is administered to an animal in order to  
 25 ameliorate one or more symptoms associated with a microbial infection. In yet another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more microbial antigens is administered to an animal in order to reduce the number of microbes in an animal.

30 Anti-C3b(i) antibodies may be administered alone or in combination with other types of anti-microbial agents. Examples of anti-microbial agents include, but are not limited to: antibiotics such as penicillin, amoxicillin, ampicillin, carbenicillin, ticarcillin, piperacillin, cephalospolin, vancomycin, tetracycline, erythromycin, amphotericin B, nystatin, metronidazole, ketoconazole, and pentamidine. Such anti-microbial agents may be  
 35 administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of a microbial infection prior to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days,

or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of anti-C3b(i) antibodies to the animal.

In a specific embodiment, anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of a microbial infection prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after) or concomitantly with the administration of plasma to the animal.

In a preferred embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of a microbial infection prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of IgG antibodies, IgM antibodies and/or one or more complement components to the animal. In another preferred embodiment, one or more anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, for the prevention or treatment of a microbial infection prior to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week before), subsequent to (*e.g.*, 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 2 days, or 1 week after), or concomitantly with the administration of antibodies immunospecific for one or more microbial antigens. Example of antibodies immunospecific for microbial antigens include, but are not limited to, antibodies immunospecific for LPS and capsular polysaccharide 5/8. In certain embodiments, animals with increased risk of a viral or bacterial infection are administered a composition of the invention. Examples of such animals include, but are not limited to human burn patients, infants, immunocompromised or immunodeficient humans, and the elderly.

The present invention provides methods for the treatment or prevention of septic shock caused by lipopolysaccharide (LPS), an endotoxin, or a constituent of the outer cell wall of a gram negative bacteria, which can be released into the circulation. In a specific embodiment, anti-C3b(i) antibodies are administered to an animal, preferably a mammal and most preferably a human, to treat or prevent septic shock. In certain embodiments, animals with increased risk of septic shock are administered a composition of the invention.



Examples of such animals include, but are not limited to human burn patients, infants, immunocompromised or immunodeficient humans, and the elderly.

In a specific embodiment, one or more anti-C3(i) antibodies are administered to an animal, preferably a mammal and most preferably in human, prior to (*e.g.*, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 6 hours, 12 hours, or 24 hours before), subsequent to (*e.g.*, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 6 hours, 12 hours, or 24 hours after) or concomitantly with any known technique for the treatment or prevention of septic shock in said animal. Examples of known techniques for the treatment or prevention of septic shock include, but are not limited to, antithrombin, intravenous immunoglobulins, cytokine antagonists (*e.g.*, anti-tumor necrosis factor (TNF) antibodies, soluble TNF receptor, anti-interleukin-1 (IL-1) antibodies, and soluble IL-1 receptor), antibiotics, and anti-inflammatory agents. The treatment and/or prevention of septic shock includes, but is not limited to, alleviating one or more symptoms associated with one or more symptoms with septic shock and the enhancement of the immune response.

In a specific embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies is administered to an animal in order to ameliorate one or more symptoms associated with septic shock. In another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and IgG and/or IgM enriched plasma is administered to an animal in order to ameliorate one or more symptoms associated with septic shock. In another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more complement components is administered to an animal in order to ameliorate one or more symptoms associated with septic shock. In yet another embodiment, a composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for lipopolysaccharide is administered to an animal in order to ameliorate one or more symptoms associated with septic shock.

Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human anti-C3b(i) antibodies, derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

### 5.7.1. GENE THERAPY

The present invention provides methods for the treatment or prevention of cancer, viral infection, and microbial infection comprising administering nucleic acid molecules encoding one or more anti-C3b(i) antibodies. In a specific embodiment, nucleic acids comprising sequences encoding one or more anti-C3b(i) antibodies are administered to treat or prevent cancer, viral infection or microbial infection, by way of gene therapy. In another embodiment, nucleic acids comprising sequences encoding one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more cancer antigens are administered to treat or prevent cancer, by way of gene therapy. In another embodiment, nucleic acids comprising sequences encoding one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more viral or microbial antigens are administered to treat or prevent viral or microbial infection, by way of gene therapy. In yet another embodiment, nucleic acids comprising sequences encoding one or more anti-C3b(i) antibodies and one or more complement components are administered to treat or prevent cancer, viral infection, or microbial infection, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a prophylactic or therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., 1993, Clinical Pharmacy 12:488-505; Wu and Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May, 1993, TIBTECH 11(5):155-215). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; and Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY.

In one aspect, a composition comprising nucleic acid sequences encoding one or more anti-C3b(i) antibodies, one or more antibodies immunospecific for cancer antigens, viral antigens or microbial antigens, and/or one or more component components in an expression vector are administered to suitable hosts. The expression of nucleic acid sequences encoding anti-C3b(i) antibodies, antibodies immunospecific for cancer antigens, viral antigens or microbial antigens, and/or component components may be regulated by any inducible, constitutive, or tissue-specific promoter known to those of skill in the art. In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression

of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

In a particular embodiment, nucleic acid molecules encoding the coding regions of anti-C3b(i) antibodies, antibodies immunospecific for cancer antigens, viral antigens or microbial antigens, and/or component components and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of said coding regions (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438).

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids *in vitro*, then transplanted into the patient. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered *in vivo*, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, *e.g.*, by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, *e.g.*, by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, *e.g.*, Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (see, *e.g.*, PCT Publications WO 92/06180 dated April 16, 1992 (Wu et al.); WO 92/22635 dated December 23, 1992 (Wilson et al.); WO92/20316 dated November 26, 1992 (Findeis et al.); WO93/14188 dated July 22, 1993 (Clarke et al.), WO 93/20221 dated October 14, 1993 (Young)). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438).

In a specific embodiment, viral vectors are used to express nucleic acid sequences. For example, a retroviral vector can be used (see Miller et al., 1993, Meth. Enzymol. 217:581-599). These retroviral vectors have been to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA. The  
5 nucleic acid sequences encoding the antibodies and/or complement components to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., 1994, Biotherapy 6:291-302, which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to  
10 chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., 1994, J. Clin. Invest. 93:644-651; Kiem et al., 1994, Blood 83:1467-1473; Salmons and Gunzberg, 1993, Human Gene Therapy 4:129-141; and Grossman and Wilson, 1993, Curr. Opin. in Genetics and Devel. 3:110-114.

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses  
15 are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, 1993, Current Opinion in Genetics and Development  
20 3:499-503 present a review of adenovirus-based gene therapy. Bout et al., 1994, Human Gene Therapy 5:3-10 demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., 1991, Science 252:431-434; Rosenfeld et al., 1992, Cell 68:143-155; Mastrangeli et al., 1993, J. Clin. Invest. 91:225-234; PCT Publication  
25 WO94/12649; and Wang, et al., 1995, Gene Therapy 2:775-783. In a preferred embodiment, adenovirus vectors are used to deliver antibodies and/or complement components to an animal in accordance with methods of the invention.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., 1993, Proc. Soc. Exp. Biol. Med. 204:289-300; U.S. Patent No. 5,436,146).  
30 In one embodiment, AAV vectors are used to delivery antibodies and/or complement components to an animal in accordance with methods of the invention.

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a  
35 selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, *e.g.*, Loeffler and Behr, 1993, *Meth. Enzymol.* 217:599-618; Cohen et al., 1993, *Meth. Enzymol.* 217:618-644; Cline, 1985, *Pharmac. Ther.* 29:69-92) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (*e.g.*, hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include, but are not limited to, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes, blood cells (*e.g.*, T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, and granulocytes) and various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, *e.g.*, as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding anti-C3b(i) antibodies, antibodies immunospecific for cancer antigens, viral antigens or microbial antigens, and/or component components are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained *in vitro* can potentially be used in accordance with this embodiment of the present invention (see *e.g.* PCT Publication WO 94/08598, dated April 28, 1994; Stemple and Anderson, 1992, *Cell* 71:973-985; Rheinwald, 1980, *Meth. Cell Bio.* 21A:229; and Pittelkow and Scott, 1986, *Mayo Clinic Proc.* 61:771).

### 5.8. DEMONSTRATION OF THERAPEUTIC OR PROPHYLACTIC UTILITY

The compositions of the invention are preferably tested *in vitro*, and then *in vivo* for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays to demonstrate the therapeutic or prophylactic utility of a composition include, the effect of a composition on a cell line, particularly one characteristic of a specific type of cancer, or a patient tissue sample. The effect of the composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. Test compositions can be tested for their ability to augment activated immune cells by contacting activated immune cells with a test composition or a control composition and determining the ability of the test composition to modulate the biological activity of the activated immune cells. The ability of a test composition to modulate the biological activity of activated immune cells can be assessed by detecting the expression of cytokines or antigens, detecting the proliferation of immune cells, detecting the activation of signaling molecules, detecting the effector function of immune cells, or detecting the differentiation of immune cells. Techniques known to those of skill in the art can be used for measuring these activities. For example, cellular proliferation can be assayed by  $^3\text{H}$ -thymidine incorporation assays and trypan blue cell counts. Cytokine and antigen expression can be assayed, for example, by immunoassays including, but are not limited to, competitive and non-competitive assay systems using techniques such as western blots, immunohistochemistry radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and FACS analysis. The activation of signaling molecules can be assayed, for example, by kinase assays and electromobility shift assays (EMSAs). The effector function of T-cells can be measured, for example, by a  $^{51}\text{Cr}$ -release assay (see, *e.g.*, Palladino et al., 1987, Cancer Res. 47:5074--5079 and Blachere et al., 1993, J. Immunotherapy 14:352-356).

Test composition can be tested for their ability to reduce tumor formation in patients (*i.e.*, animals) suffering from cancer. Test compositions can also be tested for their ability to reduce viral load or bacterial numbers *in vitro* and *in vivo* (*e.g.*, in patients suffering from an infectious disease) utilizing techniques known to one of skill in the art. Test compositions can also be tested for their ability to alleviate of one or more symptoms associated with cancer or an infectious disease (*e.g.*, a viral or microbial infection). Test compositions can also be tested for their ability to decrease the time course of the infectious disease. Further, test compositions can be tested for their ability to increase the survival

period of patients suffering from cancer or an infectious disease (e.g., a viral or microbial infection). Techniques known to those of skill in the art can be used to analyze or test the to function of the test compositions in patients.

5 In various embodiments, with the invention, *in vitro* assays which can be used to determine whether administration of a specific composition is indicated, include *in vitro* cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a composition, and the effect of such composition upon the tissue sample is observed.

10 Compositions for use in therapy can be tested in suitable animal model systems prior to testing in humans, including but not limited to rats, mice, chicken, cows, monkeys, rabbits, etc. For *in vivo* testing, prior to administration to humans, any animal model system known in the art may be used.

#### 15 5.9. **THERAPEUTIC/PROPHYLACTIC ADMINISTRATION AND COMPOSITION**

20 The invention provides methods of preventing and treating cancer, viral infection, microbial infection, and septic shock by administering to an animal (e.g., cows, pigs, horses, chickens, cats, dogs, humans, etc.) an effective amount of a composition of the invention. In certain embodiments, compositions of the invention are administered to human burn patients, infants, immunocompromised or immunodeficient humans, or the elderly. Compositions of the invention include any one of the following or a combination of any of the following: one or more anti-C3b(i) antibodies, one or more antibodies immunospecific for one or more cancer antigens, one or more antibodies immunospecific for one or more viral antigens, one or more antibodies immunospecific for one or more microbial antigens, one or more complement components, nucleic acid sequences encoding one or more anti-C3b(i) antibodies, nucleic acids encoding one or more antibodies immunospecific for one or more cancer cell antigens; nucleic acids encoding one or more antibodies immunospecific for one or more viral antigens; nucleic acids encoding one or more complement components, nucleic acids encoding one or more microbial antigens, one or more antibodies immunospecific for lipopolysaccharide, an endotoxin, or a constituent of the outer wall of a gram negative bacteria, and/or nucleic acids encoding one or more antibodies immunospecific for lipopolysaccharide, an endotoxin, or a constituent of the outer wall of a gram negative bacteria. In a preferred aspect, a composition of the invention is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects).

35 Various delivery systems are known and can be used to administer a composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant

cells capable of expressing the compound, receptor-mediated endocytosis (see, *e.g.*, Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

In another embodiment, the composition can be delivered in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527-1533; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see generally ibid.*)

In yet another embodiment, the composition can be delivered in a controlled release or sustained release system. In one embodiment, a pump may be used (*see* Langer, *supra*; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al., 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321:574). In another embodiment, polymeric materials can be used in a controlled release system (*see* Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., 1983, Macromol. Sci. Rev. Macromol. Chem. 23:61; *see also* Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target (*e.g.*, the brain, kidney, stomach, pancreas, and lung), thus requiring only a fraction of the



systemic dose (*see, e.g.*, Goodson, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (1990, Science 249:1527-1533).

5 In a specific embodiment where the composition of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.*, by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment  
10 (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see *e.g.*, Joliot et al., 1991, Proc. Natl. Acad. Sci. USA 88:1864-1868), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

15 The present invention also provides pharmaceutical compositions. Such compositions comprise a prophylactically or therapeutically effective amount of one or more anti-C3b(i) antibodies, one or more antibodies immunospecific for one or more cancer antigens, one or more antibodies immunospecific for one or more viral antigens, one or more antibodies immunospecific for one or more microbial antigens, one or more  
20 complement components, or a combination thereof, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle  
25 with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid  
30 carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the  
35 form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard

carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the  
5 compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration  
10 to human beings. Typically, pharmaceutical compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the pharmaceutical composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder  
15 or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to  
20 administration.

The pharmaceutical compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium,  
25 ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of a composition of the invention which will be effective in the treatment or prevention of cancer, viral infection, or microbial infection can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to  
30 help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight.  
35 Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

For antibodies, the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50  
5 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (*e.g.*, into the brain). A method for lipidation of antibodies is  
10 described by Cruikshank et al., 1997, J. Acquired Immune Deficiency Syndromes and Human Retrovirology 14:193).

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form  
15 prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

#### 5.10. DIAGNOSIS AND IMAGING OF CANCER

20 Labeled antibodies, derivatives and analogs thereof, which specifically bind to C3b(i) can be used for diagnostic purposes to detect, diagnose, or monitor cancer. In a preferred embodiment, anti-C3b(i) antibodies which immunospecifically bind to C3b(i) covalently bound to IgG or IgM antibodies, or C3b(i) covalently bound to a cancer cell are used for diagnostic purposes to detect, diagnosis, or monitor cancer. In a preferred  
25 embodiment, cancer is detected in the patient. The patient is an animal, preferably a mammal and most preferably a human.

In one embodiment, diagnosis is carried out by: a) administering to an animal an effective amount of a labeled molecule which immunospecifically binds to C3b(i) or C3b(i) covalently linked to a second molecule; b) waiting for a time interval following the  
30 administering for permitting the labeled molecule to preferentially concentrate at any cancerous site in the animal (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates the presence of cancer. In one embodiment, diagnosis is carried out by: a) administering to an  
35 animal an effective amount of a labeled molecule which immunospecifically binds to C3b(i) or C3b(i) covalently linked to a second molecule prior to, subsequent to, or concomitantly with the administration of IgG antibody, IgM antibody, plasma, one or more complement

- components, and/or one or more antibodies which immunospecifically bind to a cancer cell antigen; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at any cancerous site in the animal (and for unbound labeled molecule to be cleared to background level); c) determining background level; and
- 5 d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates the presence of cancer. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

- The invention provides methods for the diagnosis or detection of cancer in an
- 10 animal, said methods comprising imaging said animal at a time interval after administering to said animal an effective amount of a labeled antibody which immunospecifically binds to C3b(i) or C3b(i) covalently linked to a second molecule, said time interval being sufficient to permit the labeled antibody to preferentially concentrate at any cancerous site in said animal, wherein detection of the labeled antibody localized at the site in the subject
- 15 indicates the presence of cancer. The invention also provides methods for the diagnosis or detection of cancer in an animal, said methods comprising imaging said animal at a time interval after administering to said animal an effective amount of a labeled antibody which immunospecifically binds to C3b(i) or C3b(i) covalently linked to a second molecule prior to, subsequent to, or concomitantly with the administration of IgG antibody, IgM antibody,
- 20 plasma, one or more complement components, and/or one or more antibodies which immunospecifically bind to a cancer cell antigen, said time interval being sufficient to permit the labeled antibody to preferentially concentrate at any cancerous site in said animal, wherein detection of the labeled antibody localized at the site in the subject indicates the presence of cancer.

- 25 Depending on several variables, including the type of label used and the mode of administration, the time interval following the administering for permitting the labeled molecule to preferentially concentrate at any cancerous site in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days
- 30 or 5 to 10 days.

In a specific embodiment, monitoring of the cancer is carried out by repeating the method for diagnosing the cancer, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

- In another specific embodiment of the invention, the density of a tumor facilitates
- 35 the detection of said tumor using anti-C3b(i) antibodies in accordance with the methods of the invention.

U.S. patent application Serial No. 60/181,143, filed February 8, 2000, in particular page 2 of said application, is incorporated herein by reference in its entirety.

#### 5.10.1. METHODS OF DETECTION AND IMAGING

5 Presence of the labeled molecule can be detected in the patient using methods known in the art for *in vivo* scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include but are not limited to: computed tomography (CT), whole body scan such as  
10 position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In  
15 another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

#### 20 5.11. KITS

The present invention also provides kits that can be used in the above methods. In one embodiment, a kit comprises one or more antibodies immunospecific for C3b(i) or C3b(i) linked (*e.g.*, covalently linked) to a second molecule, in one or more containers. In another embodiment, a kit comprises one or more antibodies immunospecific for C3b(i) or  
25 C3b(i) linked (*e.g.*, covalently linked) to a second molecule and IgM antibody, in one or more containers. In another embodiment, a kit comprises one or more antibodies immunospecific for C3b(i) or C3b(i) linked (*e.g.*, covalently linked) to a second molecule and IgG antibody, in one or more containers. In another embodiment, a kit comprises one or more antibodies immunospecific for C3b(i) or C3b(i) linked (*e.g.*, covalently linked) to a  
30 second molecule and one or more complement components, in one or more containers. In another embodiment, a kit comprises one or more antibodies immunospecific for C3b(i) or C3b(i) linked (*e.g.*, covalently linked) to a second molecule and one or more antibodies immunospecific for one or more cancer cell antigens, viral antigens, or microbial antigens, in one or more containers. In another embodiment, a kit comprises one or more antibodies  
35 immunospecific for C3b(i) or C3b(i) linked (*e.g.*, covalently linked) to a second molecule, IgM or IgG antibody, and one or more complement components in one or more containers. In yet another embodiment, a kit comprises one or more antibodies immunospecific for

C3b(i) or C3b(i) linked (*e.g.*, covalently linked) to a second molecule, one or more antibodies immunospecific for one or more cancer cell antigens, viral antigens or microbial antigens, and one or more complement components, in one or more containers.

Preferably, the kits of the present invention further comprise a control antibody  
5 which is not immunospecific for C3b(i) or C3b(i) linked (*e.g.*, covalently linked) to a second molecule. In a specific embodiment, the kits of the present invention contain a labeled C3b(i) immunospecific antibody. In a preferred embodiment, the kits of the invention contain a C3b(i) immunospecific antibody conjugated to a therapeutic agent. In another preferred embodiment, the kits of the present invention contain a C3b(i) specific  
10 antibody conjugated to a diagnostic agent. In yet another preferred embodiment, the kits of the present invention contain a purified C3b(i) immunospecific antibody. In yet another embodiment, the kits of the present invention contain anti-C3b(i) antibodies which immunospecifically bind to C3b(i) covalently bound to IgG or IgM antibody, or C3b(i) covalently bound to a cancer cell, virus, or microbe.

15 In certain embodiments, the kits of the invention contain instructions for the use of the antibodies for the treatment, prevention or diagnosis of cancer, viral infections, or microbial infections.

#### 6. EXAMPLE: C3b(i) AS A TUMOR-SPECIFIC ANTIGEN

20 The following example demonstrates that after opsonization of prostate tumor cells, C3b(i) can function as a tumor-specific antigen. Antibodies specific for C3b(i) can be utilized to target tumor cells for the delivery of therapeutic or diagnostic agents, including cytotoxic, chemotherapeutic, immune-enhancing drugs, radioactive compounds, genetic material and immune effector cells.

25 LNCaP and lineage-derived C4-2 human prostate cancer cell lines were utilized in this example to demonstrate the use of C3b(i) as a target for immunotherapy. The LNCaP/C4-2 progression model recapitulates progression of human neoplastic prostate disease from an androgen-responsive and minimally metastatic (LNCaP cells) to an androgen-refractory (defined as being able to proliferate in castrate hosts) and highly  
30 aggressive phenotype (C4-2 subline) (Thalmann et al., 1994, *Canc. Res.* 54:2577-81; Chung et al., 1996, *Urol. Oncol.* 2:99-128; Hyytinen et al., 1997, *Br. J. Cane.* 75:190-5). It shares remarkable similarities with clinical human prostate cancer both in its genotypic and phenotypic changes. Furthermore, the LNCaP/C4-2 progression model has been shown to be a powerful tool for evaluating anti-prostate cancer therapeutic approaches both *in vitro*  
35 and *in vivo* (Chung et al., 1997, *Acta Urol. Jap.* 43:815-20), especially with regard to hormone-refractory disease, for which few effective or durable treatment options currently exist (Scher et al., 1994, *Sem Oncol* 21:630-56).

## 6.1. MATERIALS AND METHODS

### Cell lines and Serum Specimens

LNCaP (American Type Culture Collection, Rockville, MD) and C4-2 (Urocor, Oklahoma City, OK) human prostate cancer cell lines were maintained in T-media with 5% heat inactivated fetal bovine serum (FBS; Gibco, Grand Island, NY). Cultures were maintained at 37°C in humidified 5% CO<sub>2</sub>, split and harvested at 80 to 90% confluence, and treated, if applicable, at 25% confluence. Cells were collected using either phosphate buffered saline (PBS) with 2.5 mM ethylenediaminetetraacetic acid (EDTA; Sigma, St. Louis, MO) or trypsin (Gibco, Grand Island, NY) diluted 1:10 in phosphate buffered saline (PBS). Samples were then washed twice in PBS by centrifugation at 450 g for 2 minutes and resuspended at a final concentration of 0.2-1 X 10<sup>7</sup> cells/ml in PBS with 1% bovine serum albumin (BSA-PBS).

Serum samples were obtained with written informed consent from normal male and female volunteers (University of Virginia, Charlottesville, VA) and from men being followed for prostate disease (University of Virginia and Eastern Virginia Medical School, Norfolk, VA). Prostate disease patients had pathologic documentation of either benign or neoplastic prostate disease. Blood was drawn into SST gel and clot activator Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ), held at room temperature for 30 min, and then centrifuged for 20 min at 700 X g to obtain serum which was stored at -80°C.

### Serum Opsonization of Tumor Cells

Harvested LNCaP and C4-2 tumor cells (1 X 10<sup>7</sup> cells/ml in BSA-PBS) were mixed with an equal volume of freshly thawed serum and gently shaken for 20 min at 37°C. The opsonized cells were washed twice and brought to a final concentration of 1 X 10<sup>7</sup> cells/ml in BSA-PBS. Alternative opsonization procedures included addition of 10 mM EDTA to sera to block all complement activation (or use of EDTA-containing plasma), addition of 10 mM ethylene glycol tetraacetic acid (EGTA) and 5 mM Mg (Mg-EGTA) to allow only alternative pathway activation, use of purified IgM (1 mg/ml, Sigma, St. Louis, MO), or use of IgM-depleted serum. In this case, IgM was removed from normal human sera (NHS) by incubating 2.5 ml of serum with 1.65 ml (settled volume) anti-human IgM agarose (Sigma, St. Louis, MO) on ice for 1 hr with gentle shaking. The depleted serum was separated from the agarose by centrifugation at 1600 X g and then stored at -80°C. ELISA determinations (not shown) demonstrated that >90% of the human IgM was specifically removed from the serum by this procedure, but the level of human IgG was reduced by less than 10%.

### Monoclonal Antibodies

IgG1 mAb 7C12, 2H11, and 8E11, specific for C3b(i); IgG1 mAb HB57, specific for human IgM; and IgG2a mAb 7G9, specific for human complement receptor 1 (CR1), have been previously reported (Ferguson et al., 1995, *Arthritis Rheum* 38:190; Taylor et al., 1989, *J. Immunol.* 143:3626; and Tomic et al., 1989, *J. Immunol. Methods* 120:241) and were used in parallel with isotype-matched controls. Anti-C3b(i) mAb 3E7 (IgG1), which bound to a different epitope and was not blocked by the other anti-C3b(i) mAb, was prepared by our previously described methods (Tomic et al., 1989, *J. Immunol. Methods* 120:241). The specificity of mAb 3E7 for C3b(i) was confirmed by indirect flow cytometry as follows. Both mAb 3E7 and 7C12 bound to serum-opsonized pig erythrocytes, as revealed by fluorescein-isothiocyanate(FITC)-labeled anti-mouse IgG. In the presence of 5 µg/ml purified, heat-treated (56°C) C3 (Quidel, San Diego, CA), binding of the mAb to opsonized pig erythrocytes was reduced by 88% and 62% respectively (results not shown). Radiolabeling of mAb with <sup>125</sup>I was performed by the Iodogen procedure (Edberg et al., 1988, *J. Immunol.* 141:4258; and Fraker et al., 1978, *Biochem. Biophys. Res. Commun.* 80:849). A bispecific mAb complex (a heteropolymer) was prepared by cross-linking mAb 3E7 with mAb 7G9 (Segal et al., 1995, *Curr Protocol Immunol* 2:131; and Taylor et al., 1997, *J. Immunol.* 97:842).

### Serum opsonization of tumor cells

Harvested LNCaP and C4-2 tumor cells (approx.  $5 \times 10^6$  cells/ml in BSA-PBS) were mixed with an equal volume of freshly thawed serum and gently shaken for 20-30 min at 37°C. The opsonized cells were washed twice and brought to a final concentration of  $5 \times 10^6$  cells/ml in BSA/PBS. Alternative opsonization procedures included addition of 10 mM EDTA to sera or the use of EDTA-containing plasma to block all complement activation, addition of 10 mM [ethylenebis (oxonitrilo)]-N,N,N',N'-tetraacetic acid (EGTA) and 5 mM Mg<sup>+2</sup> (MgEGTA) to allow only alternative pathway activation, the use of purified IgM (1 mg/ml, Sigma, St. Louis, MO), or the use of IgM-depleted serum. In the latter case, IgM was removed from NHS by incubating 2.5 ml serum with 1.65 ml (settled volume) anti-(human IgM) linked to agarose (Sigma, St. Louis, Mo.) on ice for 1 h with gentle shaking. The depleted serum was separated from the agarose by centrifugation at 1,600 g and then stored at -80°C. Enzyme-linked immunosorbent assay determinations (not shown) demonstrated that more than 90% of the human IgM was specifically removed from the serum by this procedure, but the level of human IgG was reduced by less than 10%.

35



### Flow cytometry and radioimmunoassays

Opsonized cancer cells were probed with FITC-labeled goat anti-(human IgM) Fc5 $\mu$  (Pierce, Rockford, Ill.), FITC-labeled goat anti-human IgG Fc (Accurate, Westbury, N.Y.), or a cocktail of the anti-C3b(i) mAb 7C12 and 8E11 (typically 200 ng each mAb/10<sup>6</sup> cells) followed by a secondary FITC-labeled goat anti-mouse IgG (Sigma, St. Louis, MO). All incubations were at 37°C for 20 min in BSA-PBS. Controls included non-opsonized cells and irrelevant isotype-matched mAb. In selected cases, cells were stained with propidium iodide (Sigma, St. Louis, MO) used at a final concentration of 2  $\mu$ g/ml in BSA/PBS for 5 min, in the dark, on ice, to ascertain IgM or C3b-opsonization of the viable cell populations only. Viability was usually above 75%. One- or two-color fluorescence analysis was performed with CellQuest software on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA).

Studies of the binding of <sup>125</sup>I-labeled anti-C3b(i) and anti-human IgM mAb to cancer cells followed previously published procedures (Edberg et al., 1988, J. Immunol. 141:4258; and Taylor et al., 1989, J. Immunol. 143:3626). Briefly, after opsonization, 5 x 10<sup>6</sup> cancer cells were incubated for 20-30 min with <sup>125</sup>I-labeled mAb 7C12, 8E11, 3E7, or HB57 (final concentrations between 0.1  $\mu$ g/ml and 10  $\mu$ g/ml) or matched-isotype controls. As a separate control for background binding, naive cancer cells were incubated with the <sup>125</sup>I-labeled mAb. The level of binding of the mAb to the cancer cells was then determined by centrifuging the sample through oil and measuring radioactive counts in the cell pellets (Ross et al., 1985, J. Immunol. 135:2005). Alternatively, in order to determine if the anti-C3b(i) mAb could bind to cancer cells *during* complement opsonization, <sup>125</sup>I-labeled mAb 3E7 or 7C12 was added directly to the incubation mixture containing cancer cells and NHS. After incubation at 37°C, the cells were spun through oil to measure mAb binding.

### Rosette experiments

Samples of 10  $\mu$ l 50% suspension of human erythrocytes (approximately 5 x 10<sup>7</sup> cells) in either BSA/PBS or plasma were incubated with 2 x 10<sup>4</sup> LNCaP cells (either non-opsonized, or serum- opsonized as described above) in the presence or absence of 20 ng anti-CR1 x anti-C3b(i)(7G9 x 3E7) heteropolymer. After 30 min at 37°C, the cell mixtures were resuspended in BSA-PBS at a final concentration of 1% erythrocytes. Light microscopy was used to evaluate the presence and extent of erythrocyte/tumor-cell rosetting.

### Immunohistochemistry

Paraffinized tissue sections with defined histopathology were deparaffinized treated with 3% hydrogen peroxide, blocked with Super Block (Scytex Laboratories, Logan, Utah), and then treated with Avidin/Biotin Block (Vector Laboratories Inc., Burlingame, Calif.).

5 Fixed sections were incubated with 4 µg/ml anti-C3b(i) IgG1mAb 7C12 and 8E11 overnight at 4°C, followed by biotinylated goat anti-mouse IgG and peroxidase-conjugated streptavidin (Biogenex Laboratories, San Ramon, CA). Subsequently, 3-amino-9-ethylcarbazole/H<sub>2</sub>O<sub>2</sub> was used as the peroxidase substrate. Mouse IgG1 was used as a negative control for staining. The presence and extent of immunohistochemical staining

10 was evaluated by light microscopy.

### Magnetic purging of cancer cells: analyses by radioimmunoassay (RIA)

Anti-C3b(i) mAb 2H1 I (which recognizes the same epitope bound by mAb 7C12 (Tosic et al., 1989, J. Immunol. Methods 120:241) or mAb 3E7 was covalently coupled to

15 amine-terminated BioMag particles (Polysciences Inc., Warrington, PA) following the manufacturer's instructions. Cancer cells were labeled with <sup>51</sup>Cr (Ferguson et al., 1995, Arthritis Rheum 38:190), opsonized with an equal volume of NHS, washed three times and then subjected to the magnetic purging protocols (see below). For experiments with blood cells in serum, blood was collected into EDTA, the cells were washed three times and re-

20 constituted into serum (or into plasma/EDTA as a control), and then <sup>51</sup>Cr-labeled cancer cells were added. Alternatively, in certain experiments, <sup>51</sup>Cr-labeled cancer cells (approx. 50,000 cells) were first mixed with aliquots of whole blood anti-coagulated in EDTA (complement activation is prevented) or in citrate (partially permissive for complement activation). After opsonization the samples were washed three times. More than 80% of

25 the <sup>51</sup>Cr label was retained by the cancer cells in all opsonization procedures.

After the opsonization steps, 25 µl containing 5 x 10<sup>4</sup> cancer cells corresponding to approx. 50,000 cpm were incubated with 100 µl BioMag particles containing approx. 100 µg anti-C3b(i) mAb, or a control irrelevant IgG antibody (goat anti-(mouse IgG) or sheep anti-FITC). After an incubation of 30 min on ice, the mixtures were placed in the

30 Polysciences BioMag 15-ml separation unit, and 7 ml BSA/PBS was added to increase the volume of the separated (unbound) supernatant. This separation procedure was repeated two more times. Material bound to the magnetic particles was counted for <sup>51</sup>Cr and, after a centrifugation step, pelleted material from the unbound supernatant (representing intact but unbound cells) was counted for <sup>51</sup>Cr as well, in order to calculate the percentage of intact

35 cells bound to the beads. Approximately 90%-95% of the initial input level of cell-associated <sup>51</sup>Cr was found in either the pelleted supernatants or was directly bound to the particles.

Effects of purging on normal cells: analyses by flow cytometry

In order to determine the effects of purging on normal cells, the same procedures, which included opsonization, washing, and reaction with the BioMag particles, were performed on aliquots of whole blood and on blood cells reconstituted in serum. In these experiments the aliquots were not mixed with  $^{51}\text{Cr}$ -labeled cancer cells in order to avoid possible contamination of the flow cytometer with radioactivity. After the whole blood samples had been processed, they were assayed by flow cytometry with a number of standard markers (see below). Finally, we obtained blood samples that were enriched for CD34-positive cells from a leukaphoresis of an oncology patient at the University of Virginia who was being treated with granulocyte-colony-stimulating factor in preparation for autologous stem cell transplantation. These samples were diluted into blood-type-matched whole blood from a normal individual (containing citrate or EDTA), or were added to washed blood cells reconstituted with serum, and subjected to the same opsonization and purging protocols.

After purging, unbound cellular fractions were reconstituted to the starting volumes and examined by flow cytometry following the manufacturers' directions for use of the developing reagents. The Becton Dickinson Multitest reagent (CN 340499, CD3 FITC/CD8 PE/CD45 PerCp/CD4 APC) was used to analyze for CD3/CD4- and CD3/CD8-positive lymphocytes. Light-scattering profiles of CD45-positive cells were used in the same experiment to count granulocytes. In separate experiments we measured CD34-positive cells by dual gating on CD45 (PerCp, BD 347474) and CD34 (APC, BD 340441, isotype control BD 340442). CD14 positive cells were identified by dual gating on CD45 and CD14 (FITC, Caltag, Burlingame, Calif., MHCDI401, isotype control MG2a01). In these measurements FluorCount Fluorospheres (Coulter, Miami, Fla., PN 2547053) were used to normalize sample volumes.

Radioimmunotherapy cytotoxicity studies

The cytotoxic effects of  $^{131}\text{I}$ -labeled anti-C3b(i) (7C12 and 8E11) mAbs on the LNCaP and C4-2 prostate cancer cell lines were evaluated as follows.  $1 \times 10^6$  cells of each prostate cancer cell line were opsonized with 25% NHS (diluted in BSA-PBS) or maintained in BSA-PBS at  $37^\circ\text{C}$  for 30 min. After washing twice with PBS, either 2  $\mu\text{g}$  or 200 ng of  $^{131}\text{I}$ -labeled 7C12+8E11 or  $^{131}\text{I}$ -labeled irrelevant mAb (diluted in BSA-PBS) was added to each set of cells and incubated at room temperature for 30 min. The cells were washed twice with PBS, and plated in triplicate in 24-well tissue culture plates (Fisher Scientific, Pittsburgh, PA) in T-media + 5% FBS at  $3 \times 10^4$  cells per well. The plates were then placed in a humidified environment at  $37^\circ\text{C}$  with 5%  $\text{CO}_2$ . A single media change was performed on day 3. On 5 (LNCaP) and 6 (C4-2) subsequent days, beginning 24 hr after

mAb treatment, the triplicate wells were harvested to evaluate cell killing by comparing differences in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide (MTT) (Sigma, St. Louis, MO) assay results.

5

## 6.2. RESULTS

### C3b(i) and IgM are deposited on prostate cancer cells

Opsonization of C4-2 prostate cancer cells (and LNCaP, see below) with normal human serum (NHS) results in deposition of substantial amounts of C3b(i) on the cells. In  
10 the representative flow-cytometry experiment displayed in FIG. 1, the effect of C3b(i) opsonization by NHS on C4-2 cells is shown in the top panel (FIG. 1A). Similar results were obtained with sera from 8 other normal individuals (data not shown). C3b(i) deposition appears to be facilitated by activation of both the classical and alternative complement pathways, but considerably less C3b(i) is demonstrable when Mg-EGTA,  
15 which allows for alternative pathway activation only, is added to the serum. Moreover, opsonization with NHS provides a source of IgM specific for the cancer cells (Fig. 1B). IgM is more readily revealed on the cancer cells when the experiment is conducted under conditions (Mg-EGTA) that block the classical pathway of complement activation, as C3b deposition via the classical pathway seems to partially block epitopes on IgM (see Table 1,  
20 below). The flow cytometry results also demonstrate that, after opsonization with serum from a prostate cancer patient, significantly less C3b(i) and IgM are deposited on the tumor cells (FIG. 1C, D). It is noteworthy, however, that C3b(i) deposition via the alternative pathway (Mg-EGTA-treated serum) is comparable for both the normal and cancer patient serum, suggesting that the alternative pathway of complement activation remains intact in  
25 serum from prostate cancer patients.

### IgM binding promotes robust cancer cell opsonization with C3b(i)

On the basis of classic studies of the mechanisms of antibody-mediated complement activation (Borsos et al., 1965, Science 150:505; Circolo et al., 1985, Mol. Immunol.  
30 22:207; and Schreiber et al., 1972, J. Clin. Invest. 51:583), it was hypothesized that the observed complement activation on the cancer cells was predominantly facilitated by the binding of serum IgM to these cells. To isolate the effects of IgM, affinity chromatography was used to remove IgM from NHS under conditions that preserve the complement activity of the serum. Both RIA and flow cytometry demonstrate that, when IgM-depleted serum is  
35 used to opsonize LNCaP or C4-2 cells, substantially less C3b(i) is deposited on the cancer cells (FIG. 2). Normal levels of C3b(i) deposition can be restored, however, when cancer cells are first incubated with whole normal human plasma containing EDTA, which blocks

both classical and alternative complement pathways. Thus, the intact plasma provides a source of human IgM sufficient to allow for robust deposition of C3b(i) on the cancer cells after they have been washed and subsequently reacted with the IgM-depleted serum, which serves as a source of complement. RIA analysis further confirms that treatment of the cancer cells with purified IgM followed by treatment with IgM-depleted serum as a complement source also results in enhanced deposition of C3b(i) on the cancer cells (FIG. 2B).

Next, the number of available epitopes on serum-opsonized cancer cells that can be targeted by anti-C3b(i) mAb was measured. Dose-response studies were performed under several conditions to estimate the number of C3b(i) sites that are generated on the cells after opsonization with NHS. The results displayed in FIG. 3 indicate that complement activation can produce in excess of 100,000 C3b(i) epitopes per cell after correction for background. It is well-known that large amounts of C3b and its breakdown products are also generated in solution during complement activation by immune complexes even if they are on cell surfaces or particulates (Circolo et al., 1984, *Mol. Immunol.* 21:191; Edberg et al., 1988, *J. Immunol.* 141 4258; and Gadd et al., 1981, *Biochem J.* 195:471), and it would be reasonable to anticipate that these fragments could compete for binding to the anti-C3b(i) mAb, depending upon the exact specificity of these mAb. In fact, in most experiments binding of <sup>125</sup>I-labeled mAb 7C12 was reduced, within experimental error, to background levels when it was present during the opsonization step. For example, radioactivity bound (used to calculate molecules bound) was  $6,700 \pm 100$  cpm for 3  $\mu$ g/ml mAb 7C12 added to the washed cells; the corresponding value for the "during" protocol was  $90 \pm 100$  cpm. Background labeling (no opsonization) was  $900 \pm 100$  cpm. However, <sup>125</sup>I-labelled mAb 3E7 is still able to bind to the cancer cells even when it is present during the opsonization step. Moreover, in certain cases, at high input concentrations (FIG. 3B; 10 $\mu$ g/ml), this mAb appears to enhance the net deposition of C3b fragments on the cancer cells. Inhibition studies (see materials and methods) with purified heat-treated C3 confirmed the specificity of mAb 3E7 for C3b(i). These findings indicate that mAb 3E7 binds preferentially to C3b(i) located on the opsonized cancer cell, and is less susceptible than mAb 7C12 to inhibition by C3b(i) fragments in the medium.

**Table 1.** C3b(i) deposition on C4-2 cells by sera from two different normal donors partially blocks the detection of human IgM by both flow cytometry and radioimmunoassay

Treatment	Log mean fluorescence intensity*		Number of bound <sup>125</sup> I-mAb	
	Anti-C3b(i)	Anti-(human IgM)	Anti-C3b(i) mAb 8E11 (mean $\pm$ SD)	Anti-human IgM) mAb HB57 (mean $\pm$ SD)
No serum	7.5	4.7	1,200 $\pm$ 270	850 $\pm$ 30
Serum	266	14.8	27,700 $\pm$ 70	3,100 $\pm$ 60
Serum + EDTA	9.1	36.8	880 $\pm$ 100	7,900 $\pm$ 30
Serum + MgEGTA	55.6	29.3	12,000 $\pm$ 50	7,300 $\pm$ 330

\* Same data presented in Fig. 1

The data strongly suggests that natural human IgM binds to surface antigens on cancer cells and facilitates activation of the classical pathway, thus allowing for deposition of large amounts of human C3b(i) on the cells. However, following complement activation and C3b(i) deposition, relatively diminished levels of cancer-cell-bound IgM can be demonstrated by flow cytometry and RIA (FIG. 1 and Table 1). This is probably due to the fact that once C3b(i) becomes covalently linked to IgM, epitopes on the IgM molecule are obstructed by C3b(i), thereby preventing the binding of anti-IgM antibodies used for flow cytometry and RIA. Deposition of C3b fragments on human IgM in immune complexes has been demonstrated in several reports (Mehta et al., 1986, J. Immunol. 136:1765; Taylor et al., 1989, J. Immunol. 143:3626; and Thornton et al., 1996, Clin. Exp. Immunol. 104:531). Therefore, some C3b(i) is complexed to the IgM on the cancer cell, and it is likely that C3b(i) is also covalently attached to glycoproteins and glycolipids on the cancer cell.

The representative data in FIG. 1 indicates that the serum from a man with prostate cancer was less effective than NHS in depositing C3b(i) on cancer cells. Several studies have previously demonstrated that the amount of IgM that can bind to cancer cells is reduced in the sera of cancer patients (Desai et al., 1995, J. Immunol. Methods 188:175; Dillman, R.O., 1994, J. Clin. Oncol. 12:1497; Gross et al., 1988, Eur. J. Cancer Clin. Oncol. 24:363; Higuchi et al., 1980, J. Clin. Lab. Immunol. 4:141; and Seegal et al., 1976, Int. Arch. Allergy Appl. Immunol. 52:205). To independently confirm these findings, sera from a number of normal individuals and men with prostate cancer were surveyed to evaluate differences in the levels of anti-tumor IgM. The experiments were conducted with sera containing 0.01 M EDTA to remove the presumed confounding and blocking effect of C3b(i) in detecting cancer-cell-bound IgM. The results, displayed in FIG. 4, indicate that in two of three experiments the level of IgM bound by cancer cells was significantly greater in normal sera than in that from prostate cancer patients. The third experiment approaches

significance and might have reached it if not for the small number of samples in the control group. In one of the surveys, we assayed for cancer-cell bound IgG in addition to IgM. As shown in FIG. 4, little if any IgG in NHS is bound to the cancer cells. However, sera from some of the cancer patients show a notable titer, revealed by the large standard deviation in the patients' group. Although the numbers are too small to draw definite conclusions, these results do suggest the possibility of an active antitumor immune response in some of the cancer patients. Elevated tumor-specific IgG in patients with cancer has been previously reported (Vetvicka et al., 1997, J. Immunol. 159:599).

10 C3b(i) deposition is tumor cell-specific

To determine the cancer-tissue specificity of the C3b(i) epitope, frozen-sectioned prostate tissue specimens with anti-C3b(i) mAb were immunohistochemically stained. The surgical specimens from 2 men undergoing transurethral resection for benign prostatic hypertrophy were used as a control. Neither control demonstrated immunohistochemical evidence of anti-C3b(i) mAb binding (FIG. 5A). Conversely, of the thirty specimens from men with prostate cancer, eight (61%) stained positively for anti-C3b(i) mAb (FIG. 5B). Furthermore, in these eight specimens, only areas of malignancy were stained; regions containing a predominance of benign cells remained negative. In only 2 specimens was staining of extremely high intensity, implying that, although complement is deposited on prostate cancer cells, inherent host complement deposition by itself provides suboptimal opsonization and systemic infusions with IgM (in the form of plasma) from normal donors may be of benefit.

25 Erythrocytes rosette with opsonized tumor cells in the presence of specific anti-CR1 x anti-C3b(i) heteropolymer

One current application for mAb in cancer immunotherapy involves the generation of bispecific reagents in which a mAb specific for a cancer cell antigen is cross-linked with a mAb specific for an effector site (e.g., Fc receptors on monocytes/macrophages, granulocytes, or natural killer cells) (Renner et al., 1995, Immunol. Rev. 145:179; and Segal DM, Bakacs T, Jost CR, Kuruez I, Sconocchia G, Titus JA (1995) T-cell targeted cytotoxicity. In: Fanger MW (ed) Bispecific antibodies. Landis. Austin, Tex, p 27-42). In this approach, immunocompetent cells can be delivered directly, and specifically, to a tumor via the guidance of the anti tumor mAb. A prototype for this approach was examined by testing whether human erythrocytes could bind to C3b(i)-opsonized cancer cells through bispecific mAb complexes (heteropolymers) specific for C3b(i) and the primate erythrocyte complement receptor (CR1). As demonstrated in FIG. 6, rosettes consisting of erythrocytes completely surrounding the opsonized tumor cells are formed in normal human plasma after

addition of the heteropolymer. In contrast, in the absence of anti-C3b(i)-specific heteropolymer, the majority of opsonized tumor cells bind no erythrocytes and a small percentage bind only two or three erythrocytes, because of a small amount of CR1-mediated immune adherence (not shown) (Okada et al., 1974, Nature 248:521). Finally, no rosettes were obtained if erythrocytes and heteropolymer were incubated with naive cancer cells (not shown).

#### Complement-opsonized cancer cells can be purged by immunomagnetic methods

One of the more recent immunotherapeutic approaches to treatment of many forms of cancer involves the purging of cancer cells from autologous bone marrow or peripheral stem cells before autologous transplantation (Tyer et al., 1996, Clin. Cancer Res. 2:81). Although this method is not currently used as a therapy for prostate cancer, the use of prostate cancer cells is a reasonable test of the potential feasibility of using complement and anti-C3b(i) mAb to remove cancer cells selectively from solution. This approach is particularly attractive because opsonized cancer cells can be washed before addition of coupled mAb, eliminating solution-phase competition by C3b(i) fragments. As shown in Table 2, opsonization of both LNCaP and C4-2 cells with NHS followed by treatment with anti-C3b(i) mAb of different specificities bound to BioMag particles leads to very efficient binding and removal of the cancer cells. It is noteworthy that mAb 3E7, which binds to the cancer cells during serum opsonization, did not block purging with mAb 2H11 (Table 2).

**Table 2** Removal of C3b(i) opsonized cancer cells by magnetic purging with anti-C3b(i) mAb. Results are means  $\pm$  SD

Cell type	Cells removed (%)		Conditions
	Naive	Opsonized	
LNCaP	13 $\pm$ 4	99.0 $\pm$ 0.2	AB <sup>+</sup> serum, 2H11 beads
C4-2	4 $\pm$ 2	98.0 $\pm$ 0.3	AB <sup>+</sup> serum, 2H11 beads
C4-2	15 $\pm$ 1	98.0 $\pm$ 0.2	O <sup>-</sup> serum, 2H11 beads
C4-2	11 $\pm$ 1	96.0 $\pm$ 0.1	O <sup>-</sup> serum, 2H11 beads mAb 3E7 present during opsonization
LNCaP	18 $\pm$ 3	98 $\pm$ 1	O <sup>+</sup> serum, 3E7 beads
LNCaP	21 $\pm$ 2	99.0 $\pm$ 0.3	O <sup>+</sup> serum, 3E7 beads 2% hematocrit <sup>a</sup>
LNCaP	20 $\pm$ 5	96 $\pm$ 1	O <sup>+</sup> serum, 3E7 beads 50% hematocrit <sup>b</sup>

<sup>a</sup> Whole blood was washed three times, and the cells reconstituted to 2% hematocrit with 50% serum



<sup>b</sup> Whole blood was washed three times, and the cells reconstituted to 50% hematocrit with serum

Robust and specific binding is demonstrable when the experiment is conducted in a reconstituted system that approximates whole blood and allows for complement activation (Table 3). When the whole-blood experiment is conducted in EDTA, which blocks complement activation, binding of the C4-2 cells to the anti-C3b(i) beads is reduced to background levels. Experiments conducted with whole blood under the two conditions that allow complement activation (serum, or citrated plasma) demonstrated a high level of binding of the C4-2 cells to the mAb 3E7 magnetic beads (Table 3). Similar experiments with reconstituted blood samples spiked with CD34-positive cells to facilitate detection by flow cytometry revealed that CD34-positive cells are not removed by the anti-C3b(i)-coated beads (3E7) after complement activation (Table 3), although there was apparently some non-specific binding of the cells to both types of bead for all conditions. Flow-cytometric analyses (Table 4) of the effect of anti-C3b magnetic bead purging on normal cells indicate no specific removal of CD4<sup>+</sup> or CD8<sup>+</sup> T lymphocytes, or granulocytes. CD14<sup>+</sup> monocytes treated with serum showed some reduction compared to controls. This reduction was not observed in citrated plasma.

**Table 3** Effects of purging on cancer and progenitor cells in whole blood. The results for targeting of C4-2 cancer cells are based on <sup>51</sup>Cr-labeled cells. The retention was determined by flow-cytometric analysis of samples spiked with CD34<sup>+</sup> cells. Results are means  $\pm$  SD.

Conditions	Targeting of C4-2 cancer cells: removal (%)		Retention of CD34 <sup>+</sup> cells after purging cells/ $\mu$ l)		
	3E7 beads	IgG beads	3E7 beads	IgG beads	No beads
50% serum <sup>a</sup>	98 $\pm$ 1	3 $\pm$ 0.3	6.5 $\pm$ 1	6.5 $\pm$ 2	17 $\pm$ 5
50% serum <sup>a</sup>	8 $\pm$ 1	5 $\pm$ 0.5			
Citrate <sup>b</sup>	84 $\pm$ 8	9 $\pm$ 3	11 $\pm$ 2	8 $\pm$ 1	21 $\pm$ 1
EDTA <sup>b</sup>	10 $\pm$ 5	13 $\pm$ 3	8 $\pm$ 2	11 $\pm$ 3	20 $\pm$ 2

<sup>a</sup> Whole blood was washed three times, and the cells reconstituted to 50% hematocrit with serum or plasma

<sup>b</sup> Whole blood anti-coagulated with citrate or EDTA

**Table 4** Flow-cytometric analyses of the effects of purging on populations of T lymphocytes, granulocytes and monocytes. Whole blood anti-coagulated with citrate or EDTA was used or washed blood cells were reconstituted to 50% hematocrit in serum. 3E7 anti-C3b(i)-coated magnetic beads, IgG beads coated with a control irrelevant antibody.

5	Condi- tions	Cell population (cells/ $\mu$ l)											
		CD3/CD4			CD3/CD8			Granulocytes			CD14		
	Bead:	3E7	Ig G	None	3E7	IgG	None	3E7	Ig G	None	3E7	IgG	None
10	50% serum	730	65	730	370	330	370	2,900	3,300	3,000	280	400	620
		750	0	900	380	340	470	3,400	00	0	500	530	540
	Citrate, expt. 1	$\pm 60$	66	800	$\pm 30$	ND	560	$\pm 500$	3,500	3,500	ND	ND	ND
	Citrate, expt. 2	600	0	910	370	370	480	2,700	00	0	370	410	580
		790	N	760	420	ND	490	3,000	ND	2,900	ND	ND	ND
15	EDTA, expt. 1	630	D		420			3,500	3,200	0			
			68						50	3,300			
	EDTA, expt. 2		0						ND	0			
			N							3,400			
			D							0			

20 By flow-cytometry experiments several other cancer cell lines, including astrocytoma (U-87 MG; ATCC), breast cancer (MDA-MB-231; ATCC), colon cancer (LoVo; ATCC), lung cancer (CCD-16Lu; ATCC), and osteosarcoma (MG-63; ATCC) were efficiently opsonized with C3b(i) by the AB-positive serum used to obtain the results shown in FIG. 1A. More than 94% of the cells registered as positive after opsonization, compared  
25 to a background level (before opsonization) of less than 5% (not shown).

#### Radiolabeled anti-C3b(i) mAbs can kill prostate cancer cells *in vitro*

Another application of cancer-specific mAbs involves the coupling of radioactive agents to the mAbs to allow for the imaging or destruction of tumors (Glennie MJ, French  
30 RR. Targeting drugs, toxins, and radionuclides with bispecific antibodies. In: Fanger MW, editor. Bispecific Antibodies. ed. Austin: RG Landis Co.; 1995, p. 107-20). The potential of this approach was examined by labeling anti-C3b(i) mAbs with  $^{131}\text{I}$ , and then testing their effectiveness in killing cancer cells in culture. After serum opsonization and reaction with the radiolabeled mAbs in solution phase (see Methods), the cells were plated. In all cases  
35 the experiments included both serum-opsonized and naive cells, as well as radiolabeled isotype-matched irrelevant mAbs. Although the level of cytotoxicity was modest,

progressive killing of serum opsonized LNCaP and C4-2 cells by the <sup>131</sup>I-labeled anti-C3b(i) mAbs over a period of 3 to 6 days was demonstrated (FIG. 7). Cell death was not observed in control cultures consisting of either nonopsonized tumor cells or <sup>131</sup>I-labeled irrelevant mAb-treated cells. LNCaP and C4-2 prostate cancer cells opsonized and treated with mAbs after being plated in tissue culture wells demonstrated similar patterns of killing (data not shown).

### 6.3. DISCUSSION

It has long been recognized that C3b and its fragments can deposit on the surface of cancer cells in patients with tumors (Okada et al., 1974, *Nature* 248:521-25; Irie et al., 1974, *Science* 186:454-456.; Vetvicka et al., 1996, *J. Clin. Invest.* 98:50-61; Vetvicka V et al., 1997, *J. Immunol.* 159:599-605; and Vetvicka et al., 1999, *Clin. Exp. Immunol.* 115:229-35). This reaction is facilitated by natural IgM. Investigations by Springer and others suggest that the natural IgM repertoire recognizes cancer cell-associated carbohydrate epitopes which are not found on normal tissue (Hakomori et al., 1996, *Canc. Res.* 56:5309-18; Castronovo et al., 1989, *J. Nat. Canc. Inst.* 81:212-6; Springer et al., 1984, *Science* 224:1198-206; Springer et al., 1997, *J. Mol. Med.* 75:594-602; and Desai et al., 1995, *J. Immunol. Methods* 188:175-85). In fact, several investigators are using carbohydrate epitopes as vaccines to induce an active immune response to certain cancers (Springer, 1984, *Science* 224:1198-206; Springer, 1997, *J. Mol. Med.* 75:594-602; Livingston et al., 1997, *Canc. Immunol. Immunotherapy* 43 :324-30; and Zhang et al., 1998, *Canc. Res.* 58:2844-9). The findings presented herein demonstrate the utility of deposited C3b(i) as a tumor-associated membrane antigen with which to design a general diagnostic and therapeutic modality.

Large amounts of C3b(i) have been shown to specifically deposit on cancer cells after opsonization with NHS (FIGS. 1, 2 and 3 and Table 1). As indicated in Figures 1 and 4, the level of the presumably protective IgM is often reduced in cancer patients, including those with breast tumors (Desai et al., 1995, *J. Immunol. Methods* 188:175-85; Seegal et al., 1976, *Int. Arch. Allergy App. Immunol.* 52:205-11; Higuchi et al., 1980, *J. Lab Chin. Immunol.* 5:407-18; and Gross et al., 1988, *Eur. J. Canc. Chin. Oncol.* 24:363-7). Therefore, the infusion of normal human plasma in some cancer patients will help to restore or enhance C3b(i) opsonization of tumor sites accessible to the bloodstream. However, even if normal human plasma deposits a large quantity of C3b(i) on the cancer cell surface, it is unlikely that this action alone will be sufficient to eradicate a tumor, since cancer cells often express high levels of complement control proteins (Gorter et al., 1996, *Lab. Invest.* 74:1039-49; Maenpaa et al., 1996, *Am J Path* 148:1139-52; and Li et al., 1997, *Int. J. Canc.* 71:1049-55). For example, the expression of CD59 ("protectin") by cancer cells blocks the

action of the membrane attack complex which might otherwise lyse the cancer cell. The results presented herein demonstrate that one approach to treating cancer is to infuse a patient with normal human plasma (to supply IgM and, if necessary, complement) and to then deliver systemically anti-neoplastic agents to the cancer cells by conjugating the agents to anti-C3b(i) mAbs, which would circulate through the body and home to sites of opsonized tumor cells.

To ensure that a sufficient quantity of therapeutic agent is delivered in close proximity to the tumor cell, mAb-based immunotherapy for cancer requires a very high level of selective and high avidity binding of the mAb to the tumor. The results indicate that at least 50,000 C3b(i) epitopes are available on opsonized prostate cancer cells and, based on the *in vitro* killing studies, this level of cancer-associated antigen should be sufficient for specific targeting of the cancer cell, enabling the delivery of abundant therapeutic or diagnostic agents.

Tumor tissue-specific delivery of therapeutic agents is crucial to avoid undesirable injury to healthy tissue. In the case of C3b(i) as a target, it is important that complement activation be limited to tumor cells. Except for a few relatively rare disease conditions (Rosse et al., 1995, Blood 86:3277-86; Morgan BP. Complement: clinical aspects and relevance to disease. ed. London: Harcourt Brace Jovanovich; 1990), the complement system is highly regulated and C3b(i) is not deposited on normal tissue. Moreover, C3b(i) deposition has been shown to be confined to areas of malignancy in human prostate tissue specimens, and is absent in benign (FIG. 5A) and hyperplastic regions (not shown). These data confirm earlier studies on breast cancer, which established a similar tumor tissue-specific pattern of opsonization (Vetvicka et al., 1997, J. Immunol. 159:599-605; Howard et al., 1979, Cancer 43:2279-87; and Niculescu et al., 1992, Am. J. Path. 140:1039-43).

Due to normal turnover, a small fraction of circulating C3 expresses antigenic epitopes similar to C3b(i), and this endogenous C3b(i)-like molecule might block the action of the anti-C3b(i) mAbs (Mollnes et al., 1987, J. Immunol. Methods 101:201-7; Petronis et al., 1998, Clin. Nuc. Med. 23:672-7). Generation of C3b fragments in the solution phase during complement activation would also tend to block binding of the mAb to cancer cells, and indeed mAb 7C12 binds to the C3b-opsonized cancer cells only after they are washed (not shown). C3b(i) covalently linked directly to IgM or to a carbohydrate on the cancer cell should, however, contain unique and specific antigenic determinants different from those expressed by C3b fragments in solution, and it should be possible to generate mAb specific for such cell-associated molecules. Indeed mAb 3E7, which was able to bind to the cancer cells during the opsonization step (Fig. 3), did not block purging with the 2H11 beads (Table 2). It is likely that other mAb can be developed that will demonstrate even greater binding specificity for C3b(i) covalently bound to the cancer cells.

The feasibility of an *ex vivo* application in which anti-C3b(i) mAb can be used to target and purge complement-opsonized cancer cells, which are first washed to remove potentially competing soluble C3b(i) fragments has been demonstrated (Tables 2 and 3). The procedure appears to spare normal cells including CD34-positive cells (Tables 3 and 4), which are most representative of progenitor cells (Bensinger, W.I., 1998, Bone Marrow Transplant 21:113; LaCasse et al., 1999, Blood 94:2901; and Vescio et al., 1999, Blood 93:1858). The therapeutic efficacy of purging for autologous transplantation remains controversial (Bensinger, W.I., 1998, Bone Marrow Transplant 21:113). It is reasonable to believe that contaminating cancer cells may indeed promote tumor resurgence after autologous transplantation (Schneiderman et al., 1998, Radiat Res 149:147; and Vescio et al., 1999, Blood 93:1858) and, as noted by Bensinger (1998, Bone Marrow Transplant 21:113), carefully controlled trials will be required to determine the efficacy of purging protocols. Several other new methods for purging cancer cells from bone marrow or stem cell preparations have recently been reported (LaCasse et al., 1999, Blood 94:2901; Lazzaro et al., 1995, Exp. Hematol. 23:1347; and Schneiderman et al., 1998, Radiat Res 149:147), and C3b(i) targeting may provide a powerful orthogonal approach. Use of these procedures in tandem with C3b(i)-based targeting may allow for highly efficacious purging of cancer cells from bone marrow or peripheral blood stem cells before autologous transplantation.

The potential use of anti-C3b(i) mAb in bispecific mAb complexes bound to either erythrocytes or immune effector cells (Gast et al., 1997, Cancer Immunol. Immunother. 45:121; Renner et al., 1995, Immunol. Rev. 145:179; Segal DM, Bakacs T, Jost CR, Kuruez I, Sconocchia G, Titus JA (1995) T-cell targeted cytotoxicity. In: Fanger MW (ed) Bispecific antibodies. Landis. Austin, Tex, p 27-42; and Taylor et al., 1997, Cancer Immunol. Immunother. 45:152) is illustrated by our rosetting data (FIG. 6). In the presence of the anti-C3b(i) x anti-CR1 heteropolymer, erythrocytes completely encircled prostate tumor cells opsonized with human serum. Circulating "micrometastatic" prostate tumor cells have been demonstrated in men with prostate cancer of varying grades and stages (Sokoloff et al., 1996, Cancer 77:1862). In one possible therapeutic approach, anti-C3b(i) heteropolymer constructs could be infused into men with prostate cancer in conjunction with, or soon after an infusion of normal serum, in order to target the tumor cells.

Once the tumor cells are opsonized, anti-C3b(i) mAbs coupled with toxic agents or radioisotopes can be administered to individuals. The potential use of this approach is illustrated in FIG. 7. When LNCaP and C4-2 cells were treated with <sup>131</sup>I-labeled specific anti-C3b(i) mAbs, only those cells that had been opsonized with NHS prior to treatment with the <sup>131</sup>I-anti-C3b(i) mAbs were killed (FIG. 7). This approach can also be utilized for diagnostic imaging purposes, similar to the PROSTASCINT™ scan, when tumor cell

deposits are effectively opsonized and then targeted with anti-C3b(i) mAb-conjugated compounds (Petronis et al., 1998, Clin. Nuc. Med. 23:672-7).

The results herein demonstrate that while opsonization with normal human serum results in the deposition of large amounts of IgM and C3b(i) on prostate cancer cells, opsonization with sera from most men with prostate cancer leads to substantially diminished levels of cell-associated IgM and C3b(i). This deficiency can be restored by the infusion of normal plasma as a source of human IgM which will ultimately allow for the opsonization of cancer cells with C3b(i). These opsonized cells will therefore present unique and specific antigenic determinants for targeting by appropriate C3b(i) mAbs.

#### 7. **EXAMPLE: EFFECT OF ANTIGEN SPECIFIC ANTIBODIES ON THE ABILITY OF ANTI-C3b(i) ANTIBODIES TO BIND TO RED BLOOD CELLS**

The following example demonstrates that the presence of an antibody that immunospecifically binds to a cancer antigen increases the ability of opsonized tumor cells to bind to erythrocytes in the presence of bispecific monoclonal antibody (heteropolymer) for C3b(i) and the complement receptor CR1.

#### **Materials & Methods**

In certain experiments, <sup>51</sup>Cr-labeled Raji cells (model for B cell lymphoma) were dispersed in either serum or in serum containing 0.01 M EDTA (which blocks complement activation). They were incubated for 30 minutes at 37°C in the presence or absence of 5 µg/ml Rituximab (Genentech, CA), to allow C3b(i) deposition. The cells were then washed three times and redispersed in normal human plasma containing human red cells at a 50 % hematocrit. In two cases the incubation mixture also contained a bispecific monoclonal antibody for C3b(i) and the complement component CR1 (HP7G9X3E7; "HP") at a concentration of 3 µg/ml. After another 30 minute incubation, 100 µl aliquots of the samples were layered on 1 ml of ficoll-hypaque and centrifuged at 500 X g for 15 minutes. The <sup>51</sup>Cr counts associated with the Raji cells were then measured in the E pellet, and in the supernatant, which is the region in which free Raji cells are found.

In other experiments, <sup>51</sup>Cr-labeled Raji cells were added to washed whole blood which was reconstituted in fresh serum. The samples were incubated for 30 minutes at 37°C in the presence of varying combinations of reagents: 5 µg/ml Rituximab; 3 µg/ml HP; Rituximab plus HP incubated together; Rituximab added 15 minutes before HP; and HP added 15 minutes before Rituximab. After another 30 minute incubation, duplicate 200 µl aliquots of the samples were layered on 1 ml of ficoll-hypaque and centrifuged at 500 X g

for 15 minutes. The  $^{51}\text{Cr}$  counts associated with the Raji cells were then measured in the E pellet, and in the supernatant, which is the region in which free Raji cells are found.

### **Results**

5 As shown in FIGS. 9 and 10, a larger percentage Rajii cells bound to erythrocytes when the Rajii cells were opsonized by serum or whole blood reconstituted in serum and Rituximab in the presence of the heteropolymer than when the Rajii cells were opsonized by serum or whole blood reconstituted in serum and Rituximab in the absence of the heteropolymer. Also, a larger percentage Rajii cells bound to erythrocytes when the Rajii  
10 cells were opsonized by serum or whole blood reconstituted in serum and Rituximab in the presence of the heteropolymer than when the Rajii cells were opsonized with serum alone or whole blood reconstituted in serum alone in the presence of the heteropolymer (FIGS. 9 and 10). Further, as shown in FIG. 10, comparable numbers of Rajii cells bound to erythrocytes when the Rajii cells were opsonized with whole blood reconstituted in serum and Rituximab  
15 in presence of the heteropolymer regardless of whether the Rituximab and heteropolymer were added to the Rajii cells concomitantly or either of them was added first. Similar results were obtained with whole blood that has not been washed. These results suggest that the addition of an antibody immunospecific for a cancer cell antigen may enhance the therapeutic effect that anti-C3b(i) antibodies in cancer patients.

20

#### **8. EXAMPLE: SERUM-MEDIATED BINDING OF BACTERIA TO ERYTHROCYTES**

Two gram negative bacteria, *Escherichia coli* and *Pseudomonas aeruginosa*, both of which can cause sepsis, were used to assess the ability of bacteria in the presence of serum  
25 to bind to erythrocytes. As shown in Table 2, in the presence of normal serum, these bacteria can activate complement, covalently capture C3b, and then bind to primate erythrocytes *via* their complement receptor 1 (CR1) which is immunospecific for C3b, the first complement activation product. Binding in sample buffers (1% BSA in phosphate buffered saline) or in serum or plasma containing EDTA (to block complement activation)  
30 averaged <15% for *E. coli*, and <12% for *P. aeruginosa*. It is important to note that only a fraction of the bacteria bind to the erythrocytes, and with time binding actually decreases (see Table 5). One possible explanation for the decrease is that C3b bound to the bacteria is converted to further breakdown products, C3bi and C3dg, and the primate erythrocyte complement receptor does not bind these ligands with any measurable affinity.

35

**Table 5.** Serum-Mediated Binding of Bacteria to Erythrocytes at 37°C is Time-Dependent

Time (mins)	Percentage Of Bacteria Bound to Erythrocytes	
	<i>E. coli</i>	<i>P. aeruginosa</i>
5	50	34
20	75	85
60	48	39
120	22	15

**9. EXAMPLE: THE EFFECT OF BISPECIFIC MONOCLONAL ANTIBODIES ON THE ABILITY OF *P. AERUGINOSA* TO BIND TO ERYTHROCYTES**

The following example demonstrates that bispecific antibodies for CR1 and C3b(i) enhance the ability of *Pseudomonas aeruginosa* to bind to erythrocytes in the presence of serum.

Green fluorescent (GP) *Pseudomonas aeruginosa* (*P. aeruginosa*) was incubated for varying periods of time at 37°C with 7G9x2H4 (a bispecific monoclonal antibody for complement receptor CR1 and a *Pseudomonas aeruginosa* antigen), 7G9x7C12 (a bispecific monoclonal antibody for complement receptor CR1 and C3b(i)), 7G9x3E7 (a bispecific monoclonal antibody for complement receptor CR1 and C3b(i)), or no heteropolymer (HP) and normal human serum containing human erythrocytes at a 30-50 % hematocrit. Following an incubation period, aliquots of the samples were diluted 100 fold and the binding of GP *P. aeruginosa* to erythrocytes was detected by flow cytometry. The percentage of bound erythrocytes was then calculated based upon the number of bound and free GP *P. aeruginosa* detected using flow cytometry. In experiment 1, a concentration of 8 µg/ml of 7G9x2H4, 7G9x7C12, or 7G9x3E7 was incubated with GP *P. aeruginosa* and erythrocytes. In this experiment, erythrocytes outnumbered the GP *P. aeruginosa* 50:1. In experiment 2, a concentration of 1.3 µg/ml of 7G9x2H4 or 7G9x3E7 was incubated with GP *P. aeruginosa* and erythrocytes. In this experiment, erythrocytes outnumbered the GP *P. aeruginosa* 10:1. In experiment 3, a concentration of 1.3 µg/ml of 7G9x2H4 or 7G9x3E7 was incubated with GP *P. aeruginosa* and erythrocytes. In this experiment, erythrocytes outnumbered the GP *P. aeruginosa* 5,000:1.

As shown in Table 6 *infra*, a larger percentage of GP *P. aeruginosa* bound to erythrocytes when incubated together for 15 minutes or more in the presence of the



bispecific monoclonal antibodies than when incubated together in the absence of heteropolymer. Also, the percentage of GP *P. aeruginosa* bound to erythrocytes in the presence of 7G9x2H4 was comparable to the percentage of GP *P. aeruginosa* bound to erythrocytes in the presence of 7G9x3E7. These results suggest that an antibody immunospecific for C3b(i) is capable of binding to microbes such as *P. aeruginosa* in serum containing complement components as well as or almost as well as an antibody immunospecific for a particular microbial antigen. Thus, these results suggest the therapeutic usefulness of anti-C3b(i) antibodies in treatment of microbial infections.

Table 6. Heteropolymers Specific for *P. aeruginosa* or Cb(i)  
Enhance Binding to Erythrocytes in the Presence of Serum

Time (mins)	Percentage of <i>P. aeruginosa</i> Bound to Erythrocytes			
	No HP	7G9x2H4	7G9x7C12	7G9x3E7
*10	87	83	84	93
*30	81	98	92	97
*90	47	97	82	98
**15	65	82	ND	82
**90	32	70	ND	81
***10	98	98	ND	98
***60	91	93	ND	98

(\*) Experiment 1; (\*\*) Experiment 2; (\*\*\*) Experiment 3; (ND) not determined

The present invention is not to be limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications cited herein are incorporated by reference in their entirety.

**What is claimed is:**

1. A composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies for use in reducing viral titer or ameliorating one or more symptoms  
5 associated with a viral infection in an animal.
2. The composition of claim 1 further comprising IgG enriched plasma.
3. The composition of claim 1 or 2 further comprising IgM enriched plasma.  
10
4. The composition of claim 1 further comprising one or more complement components.
5. A composition comprising a therapeutically effective amount of one or more  
15 nucleic acid sequences encoding one or more anti-C3(i) antibodies for use in reducing viral titer or ameliorating one or more symptoms associated with a viral infection in an animal.
6. The composition of claim 5 further comprising one or more nucleic acid sequences encoding one or more complement components.  
20
7. The composition of claim 5 or 6 further comprising one or more nucleic acid sequences encoding one or more antibodies immunospecific for one or more viral antigens.
8. A composition comprising a therapeutically effective amount of one or more  
25 anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more viral antigens for use in reducing viral titer or ameliorating one or more symptoms associated with a viral infection in an animal.
9. The composition of claim 8 further comprising one or more complement  
30 components.
10. A composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies for use in reducing microbial numbers or ameliorating one or more symptoms associated with a microbial infection an animal.  
35
11. The composition of claim 10 further comprising IgG enriched plasma.

12. The composition of claim 10 or 11 further comprising IgM enriched plasma.
13. The composition of claim 10 further comprising one or more complement components.
- 5 14. A composition comprising a therapeutically effective amount of one or more nucleic acid sequences encoding one or more anti-C3b(i) antibodies for use in reducing microbial numbers or ameliorating one or more symptoms associated with a microbial infection in an animal.
- 10 15. The composition of claim 14 further comprising one or more nucleic acid sequences encoding one or more complement components.
16. The composition of claim 14 or 15 further comprising one or more nucleic acid sequences encoding one or more antibodies immunospecific for one or more microbial antigens.
- 15 17. A composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more microbial antigens for use in reducing microbial numbers or ameliorating one or more symptoms associated with a microbial infection in an animal.
- 20 18. The composition of claim 17 further comprising one or more complement components.
- 25 19. A composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies for use in ameliorating one or more symptoms associated with septic shock in an animal.
- 30 20. The composition of claim 19 further comprising IgG enriched plasma.
21. The composition of claim 19 or 20 further comprising IgM enriched plasma.
22. The composition of claim 19 further comprising one or more complement components.
- 35

23. A composition comprising a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for lipopolysaccharide, an endotoxin, or a constituent of the outer wall of a gram negative bacteria for use in ameliorating one or more symptoms associated with septic shock in an animal.

5

24. The composition of claim 23 further comprising one or more complement components.

25. The composition of claim 1, 8, 10, 17, 19 or 23 in which at least one of the anti-C3b(i) antibodies is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen.

10

26. The composition of claim 1, 8, 10, 17, 19 or 23 in which at least one of the anti-C3b(i) antibodies is a monoclonal antibody or Fab fragment.

15

27. The composition of claim 25 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer cell or erythrocyte.

28. The composition of claim 25 in which the effector cell is an erythrocyte.

20

29. The composition of claim 25 in which the antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64 or CD89.

30. The composition of claim 25 wherein the bispecific antibody is bound *ex vivo* to the effector cell.

25

31. The composition of claim 1, 8, 10, 17, 19 or 23 in which at least one of the anti-C3b(i) antibodies is conjugated to a therapeutic agent.

32. The composition of claim 1, 8, 10 17, 19 or 23 in which the animal is a human.

30

33. The composition of claim 32, wherein the human is immunocompromised, immunodeficient, elderly, suffering from burns, or an infant.

34. The composition of claim 26 in which the monoclonal antibody is a human or humanized monoclonal antibody.

35

35. The composition of claim 1 or 8 in which at least one of the viral antigens is HIV gp120, influenza neuraminidase, influenza hemagglutinin, or RSV F glycoprotein.

36. The composition of claim 10 or 17 in which at least one of the microbial  
5 antigens is lipopolysaccharide.

37. The composition of claim 1 or 8 in which the viral infection is caused by a retrovirus, a herpes virus, an arenavirus, a paramyxovirus, an adenovirus, a bunyavirus, a coronavirus, a filovirus, a flavivirus, a hepadnavirus, an orthomyovirus, a papovavirus, a  
10 picornavirus, a poxvirus, a reovirus, a togavirus, or a rhabdovirus.

38. The composition of claim 10 or 17 in which the microbial infection is a yeast infection, fungal infection, protozoan infection or bacterial infection.

39. The composition of claim 38 in which the bacterial infection is caused by *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*,  
15 *Pseudomonas aeruginosa*, *Campylobacter* (*Vibrio*) *fetus*, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Treponema pallidum*, *Treponema pertenue*, *Treponema carateneum*,  
20 *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma spp.*, *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia spp.*, or *Helicobacter pylori*.

30

35

1/10




FIG. 1B




FIG. 1D




FIG. 1A




FIG. 1C

2/10




FIG. 2A




FIG. 2B

3/10




FIG. 3A





FIG. 3B



4/10



**FIG. 4**

5/10




FIG.5A




FIG.5B

6/10




FIG.6

7/10




FIG. 7A




FIG. 7B

8/10




FIG.8

9/10

RAJI CELLS OPSONIZED WITH SERUM AND RITUXIMAB ARE BOUND TO ERYTHROCYTES  
VIA AN ANTI-CR1 X ANTI-C3bi HP





FIG.9

10/10

BINDING OF OPSONIZED RAJI CELLS\* TO ERYTHROCYTES IN THE  
PRESENCE OF RITUXIMAB AND AN ANTI-CR1 X ANTI-C3bi HP



\* WASHED WHOLE BLOOD RECONSTITUTED IN SERUM

FIG.10

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**